<SEC-DOCUMENT>0001628280-23-014859.txt : 20230502
<SEC-HEADER>0001628280-23-014859.hdr.sgml : 20230502
<ACCEPTANCE-DATETIME>20230502160944
ACCESSION NUMBER:		0001628280-23-014859
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		14
CONFORMED PERIOD OF REPORT:	20230502
ITEM INFORMATION:		Results of Operations and Financial Condition
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20230502
DATE AS OF CHANGE:		20230502

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			ARROWHEAD PHARMACEUTICALS, INC.
		CENTRAL INDEX KEY:			0000879407
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				460408024
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			0930

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-38042
		FILM NUMBER:		23879017

	BUSINESS ADDRESS:	
		STREET 1:		177 E COLORADO BLVD
		STREET 2:		SUITE 700
		CITY:			PASADENA
		STATE:			CA
		ZIP:			91105
		BUSINESS PHONE:		626-696-4702

	MAIL ADDRESS:	
		STREET 1:		177 E COLORADO BLVD
		STREET 2:		SUITE 700
		CITY:			PASADENA
		STATE:			CA
		ZIP:			91105

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	ARROWHEAD RESEARCH CORP
		DATE OF NAME CHANGE:	20040112

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	INTERACTIVE GROUP INC
		DATE OF NAME CHANGE:	20020509

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	INTERACTIVE INC
		DATE OF NAME CHANGE:	19940224
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>arwr-20230502.htm
<DESCRIPTION>8-K
<TEXT>
<XBRL>
<?xml version="1.0" ?><!--XBRL Document Created with Wdesk from Workiva--><!--Copyright 2023 Workiva--><!--r:18e5b2ff-3fc7-4ce3-bcba-5f3605a5ad33,g:f131945f-82e3-4fa2-aa9b-762f5362ea7f,d:b5e4cfe3bf2e484f911dbe766099d900--><html xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2020-02-12" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:dei="http://xbrl.sec.gov/dei/2022" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns="http://www.w3.org/1999/xhtml" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xml:lang="en-US"><head><meta http-equiv="Content-Type" content="text/html"/>


<title>arwr-20230502</title></head><body><div style="display:none"><ix:header><ix:hidden><ix:nonNumeric contextRef="i5f763463f13c4c3d89339b87605a4525_D20230502-20230502" name="dei:EntityCentralIndexKey" id="id3VybDovL2RvY3MudjEvZG9jOmI1ZTRjZmUzYmYyZTQ4NGY5MTFkYmU3NjYwOTlkOTAwL3NlYzpiNWU0Y2ZlM2JmMmU0ODRmOTExZGJlNzY2MDk5ZDkwMF80L2ZyYWc6ZjAwYWE3MTEwODdhNDc1Nzg5NjkzMzljMjkyNDNjNGEvdGFibGU6ZTk0NTYwZDhiYTM1NGZiMTg5ZWM5ZjRiMWNiNzY1NjYvdGFibGVyYW5nZTplOTQ1NjBkOGJhMzU0ZmIxODllYzlmNGIxY2I3NjU2Nl8yLTEtMS0xLTU5MzYw_a782bf31-b7dc-4fda-b3c0-91842cd5491f">0000879407</ix:nonNumeric><ix:nonNumeric contextRef="i5f763463f13c4c3d89339b87605a4525_D20230502-20230502" name="dei:AmendmentFlag" format="ixt:fixed-false" id="id3VybDovL2RvY3MudjEvZG9jOmI1ZTRjZmUzYmYyZTQ4NGY5MTFkYmU3NjYwOTlkOTAwL3NlYzpiNWU0Y2ZlM2JmMmU0ODRmOTExZGJlNzY2MDk5ZDkwMF80L2ZyYWc6ZjAwYWE3MTEwODdhNDc1Nzg5NjkzMzljMjkyNDNjNGEvdGFibGU6ZTk0NTYwZDhiYTM1NGZiMTg5ZWM5ZjRiMWNiNzY1NjYvdGFibGVyYW5nZTplOTQ1NjBkOGJhMzU0ZmIxODllYzlmNGIxY2I3NjU2Nl8zLTEtMS0xLTU5MzYw_bfb933ef-27a4-4036-b680-89df7c81dc87">FALSE</ix:nonNumeric></ix:hidden><ix:references xml:lang="en-US"><link:schemaRef xlink:type="simple" xlink:href="arwr-20230502.xsd"></link:schemaRef></ix:references><ix:resources><xbrli:context id="i5f763463f13c4c3d89339b87605a4525_D20230502-20230502"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2023-05-02</xbrli:startDate><xbrli:endDate>2023-05-02</xbrli:endDate></xbrli:period></xbrli:context></ix:resources></ix:header></div><div id="ib5e4cfe3bf2e484f911dbe766099d900_1"></div><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:4pt"><td colspan="3" style="border-top:0.75pt solid #000000;padding:0 1pt"></td></tr></table></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:15pt;font-weight:700;line-height:115%">UNITED STATES </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:15pt;font-weight:700;line-height:115%">SECURITIES AND EXCHANGE COMMISSION </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%">WASHINGTON, D.C. 20549 </span></div><div style="margin-bottom:1pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:22.878%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:4pt"><td colspan="3" style="border-bottom:0.75pt solid #000000;padding:0 1pt"></td></tr></table></div><div style="margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:15pt;font-weight:700;line-height:115%">FORM <ix:nonNumeric contextRef="i5f763463f13c4c3d89339b87605a4525_D20230502-20230502" name="dei:DocumentType" id="id3VybDovL2RvY3MudjEvZG9jOmI1ZTRjZmUzYmYyZTQ4NGY5MTFkYmU3NjYwOTlkOTAwL3NlYzpiNWU0Y2ZlM2JmMmU0ODRmOTExZGJlNzY2MDk5ZDkwMF8xL2ZyYWc6NzJmNjBkNjM5YmI4NGIwYWFhOThjM2NlNGNjYjlmMWEvdGV4dHJlZ2lvbjo3MmY2MGQ2MzliYjg0YjBhYWE5OGMzY2U0Y2NiOWYxYV8xMjIw_12a6e8c1-5827-416b-9917-582b2733b13c">8-K</ix:nonNumeric></span></div><div style="margin-bottom:1pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:22.878%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:4pt"><td colspan="3" style="border-bottom:0.75pt solid #000000;padding:0 1pt"></td></tr></table></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%">CURRENT REPORT </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%">PURSUANT TO SECTION 13 OR 15(D) OF</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%">THE SECURITIES EXCHANGE ACT OF 1934 </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%"><ix:nonNumeric contextRef="i5f763463f13c4c3d89339b87605a4525_D20230502-20230502" name="dei:DocumentPeriodEndDate" format="ixt:date-monthname-day-year-en" id="id3VybDovL2RvY3MudjEvZG9jOmI1ZTRjZmUzYmYyZTQ4NGY5MTFkYmU3NjYwOTlkOTAwL3NlYzpiNWU0Y2ZlM2JmMmU0ODRmOTExZGJlNzY2MDk5ZDkwMF8xL2ZyYWc6NzJmNjBkNjM5YmI4NGIwYWFhOThjM2NlNGNjYjlmMWEvdGV4dHJlZ2lvbjo3MmY2MGQ2MzliYjg0YjBhYWE5OGMzY2U0Y2NiOWYxYV8xODM_e06d0e4d-eb45-4a52-9c8f-8fa06f3b63c4">May 2, 2023</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%">Date of Report </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">(Date of earliest event reported)</span></div><div style="margin-bottom:1pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:22.878%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:4pt"><td colspan="3" style="border-bottom:0.75pt solid #000000;padding:0 1pt"></td></tr></table></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:15pt;font-weight:700;line-height:115%"><ix:nonNumeric contextRef="i5f763463f13c4c3d89339b87605a4525_D20230502-20230502" name="dei:EntityRegistrantName" id="id3VybDovL2RvY3MudjEvZG9jOmI1ZTRjZmUzYmYyZTQ4NGY5MTFkYmU3NjYwOTlkOTAwL3NlYzpiNWU0Y2ZlM2JmMmU0ODRmOTExZGJlNzY2MDk5ZDkwMF8xL2ZyYWc6NzJmNjBkNjM5YmI4NGIwYWFhOThjM2NlNGNjYjlmMWEvdGV4dHJlZ2lvbjo3MmY2MGQ2MzliYjg0YjBhYWE5OGMzY2U0Y2NiOWYxYV8xMjIx_b81e1b74-0563-41fa-9c18-1d1d7febca6e">Arrowhead Pharmaceuticals, Inc.</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(Exact name of registrant as specified in its charter) </span></div><div style="margin-bottom:1pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:22.878%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:4pt"><td colspan="3" style="border-bottom:0.75pt solid #000000;padding:0 1pt"></td></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> </span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.696%"><tr><td style="width:1.0%"></td><td style="width:31.726%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.559%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:31.726%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.559%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:31.730%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonNumeric contextRef="i5f763463f13c4c3d89339b87605a4525_D20230502-20230502" name="dei:EntityIncorporationStateCountryCode" format="ixt-sec:stateprovnameen" id="id3VybDovL2RvY3MudjEvZG9jOmI1ZTRjZmUzYmYyZTQ4NGY5MTFkYmU3NjYwOTlkOTAwL3NlYzpiNWU0Y2ZlM2JmMmU0ODRmOTExZGJlNzY2MDk5ZDkwMF8xL2ZyYWc6NzJmNjBkNjM5YmI4NGIwYWFhOThjM2NlNGNjYjlmMWEvdGFibGU6Nzk3MTE1MTk1NDUwNDY3NWE4OThiZGQyMDQxOWRjMzgvdGFibGVyYW5nZTo3OTcxMTUxOTU0NTA0Njc1YTg5OGJkZDIwNDE5ZGMzOF8wLTAtMS0xLTU5MzYw_15258b8d-94f1-4913-9201-ffe2e06e274b">Delaware</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonNumeric contextRef="i5f763463f13c4c3d89339b87605a4525_D20230502-20230502" name="dei:EntityFileNumber" id="id3VybDovL2RvY3MudjEvZG9jOmI1ZTRjZmUzYmYyZTQ4NGY5MTFkYmU3NjYwOTlkOTAwL3NlYzpiNWU0Y2ZlM2JmMmU0ODRmOTExZGJlNzY2MDk5ZDkwMF8xL2ZyYWc6NzJmNjBkNjM5YmI4NGIwYWFhOThjM2NlNGNjYjlmMWEvdGFibGU6Nzk3MTE1MTk1NDUwNDY3NWE4OThiZGQyMDQxOWRjMzgvdGFibGVyYW5nZTo3OTcxMTUxOTU0NTA0Njc1YTg5OGJkZDIwNDE5ZGMzOF8wLTItMS0xLTU5MzYw_18062f83-e7c6-449b-acca-a71a8c14d186">001-38042</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonNumeric contextRef="i5f763463f13c4c3d89339b87605a4525_D20230502-20230502" name="dei:EntityTaxIdentificationNumber" id="id3VybDovL2RvY3MudjEvZG9jOmI1ZTRjZmUzYmYyZTQ4NGY5MTFkYmU3NjYwOTlkOTAwL3NlYzpiNWU0Y2ZlM2JmMmU0ODRmOTExZGJlNzY2MDk5ZDkwMF8xL2ZyYWc6NzJmNjBkNjM5YmI4NGIwYWFhOThjM2NlNGNjYjlmMWEvdGFibGU6Nzk3MTE1MTk1NDUwNDY3NWE4OThiZGQyMDQxOWRjMzgvdGFibGVyYW5nZTo3OTcxMTUxOTU0NTA0Njc1YTg5OGJkZDIwNDE5ZGMzOF8wLTQtMS0xLTU5MzYw_3054eb2a-89a7-449e-b5b5-26cce5bee138">46-0408024</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:115%">(State or other jurisdiction</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:115%">of incorporation)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:115%">(Commission</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:115%">File Number)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:115%">(IRS Employer</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:115%">Identification No.)</span></div></td></tr></table></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%"> </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonNumeric contextRef="i5f763463f13c4c3d89339b87605a4525_D20230502-20230502" name="dei:EntityAddressAddressLine1" id="id3VybDovL2RvY3MudjEvZG9jOmI1ZTRjZmUzYmYyZTQ4NGY5MTFkYmU3NjYwOTlkOTAwL3NlYzpiNWU0Y2ZlM2JmMmU0ODRmOTExZGJlNzY2MDk5ZDkwMF8xL2ZyYWc6NzJmNjBkNjM5YmI4NGIwYWFhOThjM2NlNGNjYjlmMWEvdGV4dHJlZ2lvbjo3MmY2MGQ2MzliYjg0YjBhYWE5OGMzY2U0Y2NiOWYxYV8xMjMy_4c73530f-c232-4df5-a138-267a5841f9ce">177 E. Colorado Blvd</ix:nonNumeric>, <ix:nonNumeric contextRef="i5f763463f13c4c3d89339b87605a4525_D20230502-20230502" name="dei:EntityAddressAddressLine2" id="id3VybDovL2RvY3MudjEvZG9jOmI1ZTRjZmUzYmYyZTQ4NGY5MTFkYmU3NjYwOTlkOTAwL3NlYzpiNWU0Y2ZlM2JmMmU0ODRmOTExZGJlNzY2MDk5ZDkwMF8xL2ZyYWc6NzJmNjBkNjM5YmI4NGIwYWFhOThjM2NlNGNjYjlmMWEvdGV4dHJlZ2lvbjo3MmY2MGQ2MzliYjg0YjBhYWE5OGMzY2U0Y2NiOWYxYV8xMjI2_c7a20f04-90e9-4306-b1f9-b0a42d620653">Suite 700</ix:nonNumeric>, <ix:nonNumeric contextRef="i5f763463f13c4c3d89339b87605a4525_D20230502-20230502" name="dei:EntityAddressCityOrTown" id="id3VybDovL2RvY3MudjEvZG9jOmI1ZTRjZmUzYmYyZTQ4NGY5MTFkYmU3NjYwOTlkOTAwL3NlYzpiNWU0Y2ZlM2JmMmU0ODRmOTExZGJlNzY2MDk5ZDkwMF8xL2ZyYWc6NzJmNjBkNjM5YmI4NGIwYWFhOThjM2NlNGNjYjlmMWEvdGV4dHJlZ2lvbjo3MmY2MGQ2MzliYjg0YjBhYWE5OGMzY2U0Y2NiOWYxYV8xMjI3_c0f045cf-86d3-4a3c-8234-4ca84ece3ada">Pasadena</ix:nonNumeric>, <ix:nonNumeric contextRef="i5f763463f13c4c3d89339b87605a4525_D20230502-20230502" name="dei:EntityAddressStateOrProvince" id="id3VybDovL2RvY3MudjEvZG9jOmI1ZTRjZmUzYmYyZTQ4NGY5MTFkYmU3NjYwOTlkOTAwL3NlYzpiNWU0Y2ZlM2JmMmU0ODRmOTExZGJlNzY2MDk5ZDkwMF8xL2ZyYWc6NzJmNjBkNjM5YmI4NGIwYWFhOThjM2NlNGNjYjlmMWEvdGV4dHJlZ2lvbjo3MmY2MGQ2MzliYjg0YjBhYWE5OGMzY2U0Y2NiOWYxYV8xMjE5_dffa0ec4-a12b-4f60-ab48-80484e921ebf">CA</ix:nonNumeric> <ix:nonNumeric contextRef="i5f763463f13c4c3d89339b87605a4525_D20230502-20230502" name="dei:EntityAddressPostalZipCode" id="id3VybDovL2RvY3MudjEvZG9jOmI1ZTRjZmUzYmYyZTQ4NGY5MTFkYmU3NjYwOTlkOTAwL3NlYzpiNWU0Y2ZlM2JmMmU0ODRmOTExZGJlNzY2MDk5ZDkwMF8xL2ZyYWc6NzJmNjBkNjM5YmI4NGIwYWFhOThjM2NlNGNjYjlmMWEvdGV4dHJlZ2lvbjo3MmY2MGQ2MzliYjg0YjBhYWE5OGMzY2U0Y2NiOWYxYV8zODE_f6c4eed2-5e8a-4871-8167-8b6a0dbbbe8e">91105</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:115%">(Address of principal executive offices, including Zip Code)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(<ix:nonNumeric contextRef="i5f763463f13c4c3d89339b87605a4525_D20230502-20230502" name="dei:CityAreaCode" id="id3VybDovL2RvY3MudjEvZG9jOmI1ZTRjZmUzYmYyZTQ4NGY5MTFkYmU3NjYwOTlkOTAwL3NlYzpiNWU0Y2ZlM2JmMmU0ODRmOTExZGJlNzY2MDk5ZDkwMF8xL2ZyYWc6NzJmNjBkNjM5YmI4NGIwYWFhOThjM2NlNGNjYjlmMWEvdGV4dHJlZ2lvbjo3MmY2MGQ2MzliYjg0YjBhYWE5OGMzY2U0Y2NiOWYxYV80NDY_291b4e61-e194-42fe-ad28-5b92de09b776">626</ix:nonNumeric>) <ix:nonNumeric contextRef="i5f763463f13c4c3d89339b87605a4525_D20230502-20230502" name="dei:LocalPhoneNumber" id="id3VybDovL2RvY3MudjEvZG9jOmI1ZTRjZmUzYmYyZTQ4NGY5MTFkYmU3NjYwOTlkOTAwL3NlYzpiNWU0Y2ZlM2JmMmU0ODRmOTExZGJlNzY2MDk5ZDkwMF8xL2ZyYWc6NzJmNjBkNjM5YmI4NGIwYWFhOThjM2NlNGNjYjlmMWEvdGV4dHJlZ2lvbjo3MmY2MGQ2MzliYjg0YjBhYWE5OGMzY2U0Y2NiOWYxYV8xMjI5_fc597201-913c-4dee-9213-cf301935eb6a">304-3400</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:115%">(Registrant&#8217;s telephone number, including area code)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:115%"> </span></div><div style="margin-bottom:1pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:22.878%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:4pt"><td colspan="3" style="border-bottom:0.75pt solid #000000;padding:0 1pt"></td></tr></table></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions: </span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:4.455%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:93.345%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonNumeric contextRef="i5f763463f13c4c3d89339b87605a4525_D20230502-20230502" name="dei:WrittenCommunications" format="ixt-sec:boolballotbox" id="id3VybDovL2RvY3MudjEvZG9jOmI1ZTRjZmUzYmYyZTQ4NGY5MTFkYmU3NjYwOTlkOTAwL3NlYzpiNWU0Y2ZlM2JmMmU0ODRmOTExZGJlNzY2MDk5ZDkwMF8xL2ZyYWc6NzJmNjBkNjM5YmI4NGIwYWFhOThjM2NlNGNjYjlmMWEvdGFibGU6NjZiNTgzZjI0M2JmNDgxMGI3MTg2NzQ3N2ZjMDdlMTEvdGFibGVyYW5nZTo2NmI1ODNmMjQzYmY0ODEwYjcxODY3NDc3ZmMwN2UxMV8wLTAtMS0xLTU5MzYw_b8483cd4-d3d9-4dd8-9203-d8eb6c32dfb9">&#9744;</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt 2px 25pt;text-align:left;text-indent:-24pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) </span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonNumeric contextRef="i5f763463f13c4c3d89339b87605a4525_D20230502-20230502" name="dei:SolicitingMaterial" format="ixt-sec:boolballotbox" id="id3VybDovL2RvY3MudjEvZG9jOmI1ZTRjZmUzYmYyZTQ4NGY5MTFkYmU3NjYwOTlkOTAwL3NlYzpiNWU0Y2ZlM2JmMmU0ODRmOTExZGJlNzY2MDk5ZDkwMF8xL2ZyYWc6NzJmNjBkNjM5YmI4NGIwYWFhOThjM2NlNGNjYjlmMWEvdGFibGU6NjZiNTgzZjI0M2JmNDgxMGI3MTg2NzQ3N2ZjMDdlMTEvdGFibGVyYW5nZTo2NmI1ODNmMjQzYmY0ODEwYjcxODY3NDc3ZmMwN2UxMV8xLTAtMS0xLTU5MzYw_c616ebf6-d6fa-4acf-a4c1-2d7ea5ed6eb3">&#9744;</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt 2px 25pt;text-align:left;text-indent:-24pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) </span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonNumeric contextRef="i5f763463f13c4c3d89339b87605a4525_D20230502-20230502" name="dei:PreCommencementTenderOffer" format="ixt-sec:boolballotbox" id="id3VybDovL2RvY3MudjEvZG9jOmI1ZTRjZmUzYmYyZTQ4NGY5MTFkYmU3NjYwOTlkOTAwL3NlYzpiNWU0Y2ZlM2JmMmU0ODRmOTExZGJlNzY2MDk5ZDkwMF8xL2ZyYWc6NzJmNjBkNjM5YmI4NGIwYWFhOThjM2NlNGNjYjlmMWEvdGFibGU6NjZiNTgzZjI0M2JmNDgxMGI3MTg2NzQ3N2ZjMDdlMTEvdGFibGVyYW5nZTo2NmI1ODNmMjQzYmY0ODEwYjcxODY3NDc3ZmMwN2UxMV8yLTAtMS0xLTU5MzYw_3e86b1d6-d0aa-4fc9-949b-7e640bf52201">&#9744;</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt 2px 25pt;text-align:left;text-indent:-24pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) </span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonNumeric contextRef="i5f763463f13c4c3d89339b87605a4525_D20230502-20230502" name="dei:PreCommencementIssuerTenderOffer" format="ixt-sec:boolballotbox" id="id3VybDovL2RvY3MudjEvZG9jOmI1ZTRjZmUzYmYyZTQ4NGY5MTFkYmU3NjYwOTlkOTAwL3NlYzpiNWU0Y2ZlM2JmMmU0ODRmOTExZGJlNzY2MDk5ZDkwMF8xL2ZyYWc6NzJmNjBkNjM5YmI4NGIwYWFhOThjM2NlNGNjYjlmMWEvdGFibGU6NjZiNTgzZjI0M2JmNDgxMGI3MTg2NzQ3N2ZjMDdlMTEvdGFibGVyYW5nZTo2NmI1ODNmMjQzYmY0ODEwYjcxODY3NDc3ZmMwN2UxMV8zLTAtMS0xLTU5MzYw_12db5cb2-b3a0-41ab-9cb2-7bc5d690e0b8">&#9744;</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt 2px 25pt;text-align:left;text-indent:-24pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Pre-commencement communications pursuant to Rule 13e-4 (c) under the Exchange Act (17 CFR 240.13e-4(c))</span></td></tr></table></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4pt;font-weight:400;line-height:115%"> </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4pt;font-weight:400;line-height:115%"> </span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:39.051%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.557%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.557%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:39.054%"></td><td style="width:0.1%"></td></tr><tr><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">Securities registered pursuant to Section 12(b) of the Act:</span></td></tr><tr><td colspan="3" style="padding:2px 2.38pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">Title of each class</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">&#160;</span></td><td colspan="3" style="padding:2px 2.78pt;text-align:center;text-indent:-0.8pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">Trading Symbol(s)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">&#160;</span></td><td colspan="3" style="padding:2px 2.38pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">Name of each exchange on which registered</span></td></tr><tr><td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 2.38pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%"><ix:nonNumeric contextRef="i5f763463f13c4c3d89339b87605a4525_D20230502-20230502" name="dei:Security12bTitle" id="id3VybDovL2RvY3MudjEvZG9jOmI1ZTRjZmUzYmYyZTQ4NGY5MTFkYmU3NjYwOTlkOTAwL3NlYzpiNWU0Y2ZlM2JmMmU0ODRmOTExZGJlNzY2MDk5ZDkwMF8xL2ZyYWc6NzJmNjBkNjM5YmI4NGIwYWFhOThjM2NlNGNjYjlmMWEvdGFibGU6MTAxNzJiOTQ0OTg1NDA3NzhmZTNlODBmYzdiYmNmYWEvdGFibGVyYW5nZToxMDE3MmI5NDQ5ODU0MDc3OGZlM2U4MGZjN2JiY2ZhYV8yLTAtMS0xLTU5MzYw_ef781d5c-8cf1-41f9-94f7-9012677bd841">Common Stock, par value $0.001 per share</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">&#160;</span></td><td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 2.38pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%"><ix:nonNumeric contextRef="i5f763463f13c4c3d89339b87605a4525_D20230502-20230502" name="dei:TradingSymbol" id="id3VybDovL2RvY3MudjEvZG9jOmI1ZTRjZmUzYmYyZTQ4NGY5MTFkYmU3NjYwOTlkOTAwL3NlYzpiNWU0Y2ZlM2JmMmU0ODRmOTExZGJlNzY2MDk5ZDkwMF8xL2ZyYWc6NzJmNjBkNjM5YmI4NGIwYWFhOThjM2NlNGNjYjlmMWEvdGFibGU6MTAxNzJiOTQ0OTg1NDA3NzhmZTNlODBmYzdiYmNmYWEvdGFibGVyYW5nZToxMDE3MmI5NDQ5ODU0MDc3OGZlM2U4MGZjN2JiY2ZhYV8yLTItMS0xLTU5MzYw_2e430b4f-6dcc-4511-8b7e-a92fd276b56d">ARWR</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">&#160;</span></td><td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 2.38pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%"><ix:nonNumeric contextRef="i5f763463f13c4c3d89339b87605a4525_D20230502-20230502" name="dei:SecurityExchangeName" format="ixt-sec:exchnameen" id="id3VybDovL2RvY3MudjEvZG9jOmI1ZTRjZmUzYmYyZTQ4NGY5MTFkYmU3NjYwOTlkOTAwL3NlYzpiNWU0Y2ZlM2JmMmU0ODRmOTExZGJlNzY2MDk5ZDkwMF8xL2ZyYWc6NzJmNjBkNjM5YmI4NGIwYWFhOThjM2NlNGNjYjlmMWEvdGFibGU6MTAxNzJiOTQ0OTg1NDA3NzhmZTNlODBmYzdiYmNmYWEvdGFibGVyYW5nZToxMDE3MmI5NDQ5ODU0MDc3OGZlM2U4MGZjN2JiY2ZhYV8yLTQtMS0xLTU5MzYw_0e78669f-314b-4f42-a21a-9de2c479d41d">The Nasdaq Global Select Market</ix:nonNumeric></span></td></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (&#167;230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (&#167;240.12b-2 of this chapter).</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> </span></div><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Emerging growth company </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonNumeric contextRef="i5f763463f13c4c3d89339b87605a4525_D20230502-20230502" name="dei:EntityEmergingGrowthCompany" format="ixt-sec:boolballotbox" id="id3VybDovL2RvY3MudjEvZG9jOmI1ZTRjZmUzYmYyZTQ4NGY5MTFkYmU3NjYwOTlkOTAwL3NlYzpiNWU0Y2ZlM2JmMmU0ODRmOTExZGJlNzY2MDk5ZDkwMF8xL2ZyYWc6NzJmNjBkNjM5YmI4NGIwYWFhOThjM2NlNGNjYjlmMWEvdGV4dHJlZ2lvbjo3MmY2MGQ2MzliYjg0YjBhYWE5OGMzY2U0Y2NiOWYxYV8xMjI1_677fa574-7029-428a-a150-d06a5307c679">&#9744;</ix:nonNumeric></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> </span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#9744;</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><div id="ib5e4cfe3bf2e484f911dbe766099d900_7"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Item 2.02 Results of Operations and Financial Condition </span></div><div style="margin-bottom:12pt;margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">On <ix:nonNumeric contextRef="i5f763463f13c4c3d89339b87605a4525_D20230502-20230502" name="dei:DocumentPeriodEndDate" format="ixt:date-monthname-day-year-en" id="id3VybDovL2RvY3MudjEvZG9jOmI1ZTRjZmUzYmYyZTQ4NGY5MTFkYmU3NjYwOTlkOTAwL3NlYzpiNWU0Y2ZlM2JmMmU0ODRmOTExZGJlNzY2MDk5ZDkwMF83L2ZyYWc6ZWI2MjQyOTA3MTBjNGJkOThiODQyMzRmNDQ3N2RkZGQvdGV4dHJlZ2lvbjplYjYyNDI5MDcxMGM0YmQ5OGI4NDIzNGY0NDc3ZGRkZF82NQ_e06d0e4d-eb45-4a52-9c8f-8fa06f3b63c4">May&#160;2, 2023</ix:nonNumeric>, Arrowhead Pharmaceuticals, Inc. announced and commented on its financial results for the second quarter ended March 31, 2023. A copy of the press release is furnished herewith as Exhibit 99.1.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">In accordance with General Instruction B.2 of Form 8-K, the information in this Current Report on Form 8-K, including Exhibit 99.1, shall not be deemed &#8220;filed&#8221; for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the &#8220;Exchange Act&#8221;), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, whether made before or after the date hereof, except as expressly set forth by specific reference in such filing to this Current Report on Form 8-K.</span></div><div><span><br/></span></div><div><span><br/></span></div><div id="ib5e4cfe3bf2e484f911dbe766099d900_10"></div><div style="-sec-extract:summary"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Item 9.01. Financial Statements and Exhibits. </span></div><div style="margin-bottom:12pt;margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(d) Exhibits </span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.393%"><tr><td style="width:1.0%"></td><td style="width:12.162%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.562%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:84.876%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">Exhibit No.</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">Description</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:114%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">99.1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="arwr-fq22023financialresul.htm">Press Release, dated May 2, 2023.</a></span></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">104</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Cover Page Interactive Data File (the cover page tags are embedded within the Inline XBRL document).</span></td></tr></table></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><div id="ib5e4cfe3bf2e484f911dbe766099d900_13"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">SIGNATURES </span></div><div style="margin-bottom:12pt;margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized. </span></div><div style="margin-bottom:20pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Date: <ix:nonNumeric contextRef="i5f763463f13c4c3d89339b87605a4525_D20230502-20230502" name="dei:DocumentPeriodEndDate" format="ixt:date-monthname-day-year-en" id="id3VybDovL2RvY3MudjEvZG9jOmI1ZTRjZmUzYmYyZTQ4NGY5MTFkYmU3NjYwOTlkOTAwL3NlYzpiNWU0Y2ZlM2JmMmU0ODRmOTExZGJlNzY2MDk5ZDkwMF8xMy9mcmFnOjNjYTYxODUzMzY0YzQ0ODE5OTEyZThlMjg2NmMxZGUzL3RleHRyZWdpb246M2NhNjE4NTMzNjRjNDQ4MTk5MTJlOGUyODY2YzFkZTNfMjA5_e06d0e4d-eb45-4a52-9c8f-8fa06f3b63c4">May&#160;2, 2023</ix:nonNumeric></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:56.969%"><tr><td style="width:1.0%"></td><td style="width:23.102%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.129%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:73.369%"></td><td style="width:0.1%"></td></tr><tr><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">ARROWHEAD PHARMACEUTICALS, INC.</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#160;</span></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">By:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">/s/ Kenneth Myszkowski</span></td></tr><tr><td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#160;</span></td><td colspan="3" style="border-top:0.75pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Kenneth Myszkowski</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Chief Financial Officer</span></td></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%"> </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div></body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>arwr-fq22023financialresul.htm
<DESCRIPTION>EX-99.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2023 Workiva -->
<title>Document</title></head><body><div id="i6390f9d2044c49f180bca06bfbe68cec_1"></div><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-align:center"><img alt="image_0a.jpg" src="image_0a.jpg" style="height:74px;margin-bottom:5pt;vertical-align:text-bottom;width:222px"></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:31.540%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.432%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:25.457%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.615%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:25.457%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.799%"></td><td style="width:0.1%"></td></tr><tr style="height:9pt"><td colspan="6" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:3.1pt;padding-right:3.1pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:133%">PRESS RELEASE</font></div><div style="padding-left:3.1pt;padding-right:3.1pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:133%">May 2, 2023</font></div></td><td colspan="6" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11.5pt;font-weight:700;line-height:100%">Arrowhead Pharmaceuticals Reports Fiscal 2023 Second Quarter Results </font></div><div style="margin-bottom:12pt;margin-top:6pt;padding-left:18pt;padding-right:18pt;text-align:center;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:174%">-</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11.5pt;font-weight:400;line-height:174%;padding-left:14.01pt">Conference Call and Webcast Today, May 2, 2023 at 4&#58;30 p.m. ET</font></div><div style="margin-bottom:12pt;margin-top:6pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:174%">PASADENA, Calif., May 2, 2023</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:174%"> &#8212; Arrowhead Pharmaceuticals, Inc. (NASDAQ&#58; ARWR) today announced financial results for its fiscal second quarter ended March 31, 2023. The company is hosting a conference call today, May 2, 2023, at 4&#58;30 p.m. ET to discuss the results.</font></div><div style="margin-bottom:12pt;margin-top:6pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:174%">Webcast and Conference Call and Details</font></div><div style="margin-bottom:12pt;margin-top:6pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:174%">Investors may access a live audio webcast on the Company's website at </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:174%;text-decoration:underline">http&#58;&#47;&#47;ir.arrowheadpharma.com&#47;events.cfm</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:174%">. A replay of the webcast will be available approximately two hours after the conclusion of the call.</font></div><div style="margin-bottom:12pt;margin-top:6pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:174%">For analysts that wish to participate in the conference call, please register at </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:174%;text-decoration:underline">https&#58;&#47;&#47;register.vevent.com&#47;register&#47;BIf9cd65655e5444119df91cd4891157f8</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:174%">. Once registered, you will receive the dial-in number and a personalized PIN code that will be required to access the call.</font></div><div style="margin-bottom:12pt;margin-top:6pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:174%">Selected Recent Events</font></div><div style="margin-bottom:12pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:174%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:174%;padding-left:14.15pt">Reported interim results from an ongoing Phase 1&#47;2 clinical study of ARO-RAGE, an investigational RNAi therapeutic for treatment for inflammatory pulmonary diseases, such as asthma. These data represent the first clinical demonstration of the potential utility of Arrowhead&#8217;s proprietary Targeted RNAi Molecule (TRiM</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7.15pt;font-weight:400;line-height:174%;position:relative;top:-3.85pt;vertical-align:baseline">TM</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:174%">) platform optimized for delivery to the lungs. Key results from Part 1 of the study in normal healthy volunteers included the following&#58;</font></div><div style="padding-left:72pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Courier New',monospace;font-size:11pt;font-weight:400;line-height:174%">o</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:174%;padding-left:11.4pt">Mean maximum reduction in soluble RAGE (sRAGE) as measured in serum after two doses of 92 mg on Day 1 and Day 29 was 80% with a maximum reduction of 90%</font></div><div style="padding-left:108pt;text-align:justify;text-indent:-18pt"><font style="font-family:'Wingdings',sans-serif;font-size:11pt;font-weight:400;line-height:174%"></font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:174%;padding-left:12.97pt">Duration of pharmacologic effect persisted for at least 6 weeks</font></div><div style="padding-left:72pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Courier New',monospace;font-size:11pt;font-weight:400;line-height:174%">o</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:174%;padding-left:11.4pt">Mean reduction in sRAGE as measured in bronchoalveolar lavage fluid (BALF) at Day 31 after a single dose of 92 mg was 75% with a maximum reduction of 92%</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="padding-left:72pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Courier New',monospace;font-size:11pt;font-weight:400;line-height:174%">o</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:174%;padding-left:11.4pt">Mean maximum reduction of 56% with a maximum reduction of 68% in serum sRAGE was also observed after a single dose of 92 mg</font></div><div style="padding-left:72pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Courier New',monospace;font-size:11pt;font-weight:400;line-height:174%">o</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:174%;padding-left:11.4pt">Safety and tolerability</font></div><div style="padding-left:108pt;text-align:justify;text-indent:-18pt"><font style="font-family:'Wingdings',sans-serif;font-size:11pt;font-weight:400;line-height:174%"></font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:174%;padding-left:12.97pt">Overall, no patterns of adverse changes in any clinical safety parameters</font></div><div style="padding-left:108pt;text-align:justify;text-indent:-18pt"><font style="font-family:'Wingdings',sans-serif;font-size:11pt;font-weight:400;line-height:174%"></font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:174%;padding-left:12.97pt">No reported serious or severe adverse events</font></div><div style="padding-left:108pt;text-align:justify;text-indent:-18pt"><font style="font-family:'Wingdings',sans-serif;font-size:11pt;font-weight:400;line-height:174%"></font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:174%;padding-left:12.97pt">No dropouts related to drug or related to adverse events</font></div><div style="margin-bottom:12pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Courier New',monospace;font-size:11pt;font-weight:400;line-height:174%">o</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:174%;padding-left:11.4pt">These results include 4 of 5 escalating dose levels. Data are not yet available for single or multiple dose cohorts at 184 mg, the highest dose being tested</font></div><div style="margin-bottom:12pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:174%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:174%;padding-left:14.15pt">Announced a planned</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11.5pt;font-weight:400;line-height:174%"> </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:174%">R&#38;D Day on June 1, 2023, which will include presentations on cardiometabolic, pulmonary, and newly announced central nervous system (CNS) pipeline programs</font></div><div style="margin-bottom:12pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Courier New',monospace;font-size:11pt;font-weight:400;line-height:174%">o</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:174%;padding-left:11.4pt">The company expanded its TRiM</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7.15pt;font-weight:400;line-height:174%;position:relative;top:-3.85pt;vertical-align:baseline">TM </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:174%">platform to include an optimized intrathecal administration for CNS delivery with good distribution throughout the brain and in all relevant brain cell types. The first development candidate to utilize this new delivery platform, ARO-SOD1, is on track for a clinical trial application filing in the third quarter of 2023 to begin clinical studies</font></div><div style="margin-bottom:12pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Courier New',monospace;font-size:11pt;font-weight:400;line-height:174%">o</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:174%;padding-left:11.4pt">In preclinical studies, ARO-SOD1 achieved 95% spinal cord tissue mRNA knockdown after a single intrathecal dose in human SOD1 transgenic rats and maintained greater than 80% spinal cord tissue mRNA knockdown three months after a single intrathecal dose in non-human primates</font></div><div style="margin-bottom:12pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:174%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:174%;padding-left:14.15pt">Earned a $40 million milestone payment from Takeda (TSE&#58;4502&#47;NYSE&#58;TAK) after the first patient was dosed in the Phase 3 REDWOOD clinical study of fazirsiran (TAK-999&#47;ARO-AAT) for the treatment of alpha-1 antitrypsin deficiency associated liver disease (AATD-LD)</font></div><div style="margin-bottom:12pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:174%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:174%;padding-left:14.15pt">Received Fast Track designation from the U.S. Food and Drug Administration (FDA) for ARO-APOC3 for reducing triglycerides in adult patients with familial chylomicronemia syndrome</font></div><div style="margin-bottom:12pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:174%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:174%;padding-left:14.15pt">Earned a $30 million milestone payment from GSK (LSE&#47;NYSE&#58; GSK) following the start of GSK&#8217;s Phase 2b trial of GSK4532990, formerly called ARO-HSD, an investigational RNAi therapeutic for the treatment of patients with non-alcoholic steatohepatitis (NASH)</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:174%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:174%;padding-left:14.15pt">Initiated dosing in a Phase 1&#47;2a single ascending dose and multiple ascending dose clinical study of ARO-MMP7, Arrowhead&#8217;s third pulmonary targeted investigational RNAi therapeutic being developed as a potential treatment for idiopathic pulmonary fibrosis</font></div><div style="margin-bottom:12pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:174%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:174%;padding-left:14.15pt">Reported interim results from an ongoing Phase 1&#47;2 clinical study of ARO-C3, an investigational RNAi therapeutic for treatment of various complement mediated diseases, demonstrating mean reductions of 88% in C3 and 91% in AH50, a marker of alternative complement pathway hemolytic activity</font></div><div style="margin-bottom:12pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:174%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:174%;padding-left:14.15pt">Regained rights to ARO-PNPLA3, formerly called JNJ-75220795, which was part of a 2018 research collaboration and option agreement between Arrowhead and Janssen Pharmaceuticals, Inc. ARO-PNPLA3 is an investigational RNAi therapeutic developed using Arrowhead&#8217;s proprietary TRiM</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7.15pt;font-weight:400;line-height:174%;position:relative;top:-3.85pt;vertical-align:baseline">TM</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:174%"> platform and designed to reduce liver expression of patatin-like phospholipase domain containing 3 (PNPLA3) as a potential treatment for patients with NASH</font></div><div style="margin-bottom:12pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:174%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:174%;padding-left:14.15pt">Announced topline results with Takeda from the Phase 2 SEQUOIA clinical study of investigational fazirsiran for the treatment of AATD-LD and provided an outline of a Phase 3 study that was co-developed by Takeda and Arrowhead and will be conducted by Takeda. Key results from SEQUOIA included the following&#58;</font></div><div style="padding-left:72pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Courier New',monospace;font-size:11pt;font-weight:400;line-height:174%">o</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:174%;padding-left:11.4pt">Fibrosis regression observed in 50% of patients receiving fazirsiran</font></div><div style="padding-left:72pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Courier New',monospace;font-size:11pt;font-weight:400;line-height:174%">o</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:174%;padding-left:11.4pt">Median reductions of 94% of Z-AAT accumulation in the liver and mean reduction of 68% in histologic globule burden</font></div><div style="padding-left:72pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Courier New',monospace;font-size:11pt;font-weight:400;line-height:174%">o</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:174%;padding-left:11.4pt">Treatment emergent adverse events were generally well balanced between fazirsiran and placebo groups</font></div><div style="margin-bottom:12pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Courier New',monospace;font-size:11pt;font-weight:400;line-height:174%">o</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:174%;padding-left:11.4pt">Results consistent with AROAAT-2002 open-label study </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:174%;text-decoration:underline">previously published in </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:174%;text-decoration:underline">The New England Journal of Medicine</font></div><div style="margin-bottom:12pt;margin-top:6pt;text-align:justify"><font><br></font></div><div style="margin-bottom:12pt"><font><br></font></div><div style="margin-bottom:12pt"><font><br></font></div><div style="margin-bottom:12pt"><font><br></font></div><div style="margin-bottom:12pt"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:133%">Selected Fiscal 2023 Second Quarter Financial Results</font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:63.988%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.953%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.337%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.953%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.169%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:133%">Three Months Ended March 31,</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt;text-indent:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%;text-decoration:underline">OPERATING SUMMARY</font></div></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:133%">2023</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:133%">2022</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="12" style="background-color:#ccedff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:center;text-indent:48pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;(unaudited)</font></div></td><td colspan="3" style="padding:0 1pt"><div style="padding-left:2.75pt;padding-right:2.75pt;text-indent:48pt"><font><br></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt;text-indent:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Revenue</font></div></td><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:133%">$          146,267</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:133%">$          151,805</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ccedff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt;text-indent:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Operating Expenses&#58;</font></div></td><td colspan="3" style="background-color:#ccedff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:133%">&#160;</font></td><td colspan="3" style="background-color:#ccedff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:133%">&#160;</font></td><td colspan="3" style="background-color:#ccedff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:133%">&#160;</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Research and development</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:right;text-indent:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;74,881 </font></div></td><td colspan="3" style="padding:0 1pt"><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:right;text-indent:9pt"><font><br></font></div></td><td colspan="3" style="padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:133%">75,985</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ccedff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">General and administrative expenses</font></div></td><td colspan="3" style="background-color:#ccedff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:right;text-indent:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;23,221 </font></div></td><td colspan="3" style="background-color:#ccedff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:right;text-indent:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</font></div></td><td colspan="3" style="background-color:#ccedff;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:133%">34,267</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total Operating Expenses</font></div></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:right;text-indent:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;98,102 </font></div></td><td colspan="3" style="padding:0 1pt"><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:right;text-indent:9pt"><font><br></font></div></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:133%">110,252</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ccedff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt;text-indent:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Operating income</font></div></td><td colspan="3" style="background-color:#ccedff;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:133%">48,165</font></td><td colspan="3" style="background-color:#ccedff;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:133%">&#160;</font></td><td colspan="3" style="background-color:#ccedff;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:133%">41,553</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Interest income</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:right;text-indent:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,560</font></div></td><td colspan="3" style="padding:0 1pt"><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:right;text-indent:9pt"><font><br></font></div></td><td colspan="3" style="padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:133%">1,054</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ccedff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt;text-indent:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;Interest expense</font></div></td><td colspan="3" style="background-color:#ccedff;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:133%">(5,067)</font></td><td colspan="3" style="background-color:#ccedff;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:133%">&#160;</font></td><td colspan="3" style="background-color:#ccedff;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:133%">-</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other, net</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:right;text-indent:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;8 </font></div></td><td colspan="3" style="padding:0 1pt"><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:right;text-indent:9pt"><font><br></font></div></td><td colspan="3" style="padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:133%">1,759</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ccedff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt;text-indent:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Income before income tax expense and noncontrolling interest</font></div></td><td colspan="3" style="background-color:#ccedff;border-top:0.5pt solid #000000;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:133%">47,676</font></td><td colspan="3" style="background-color:#ccedff;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:133%">&#160;</font></td><td colspan="3" style="background-color:#ccedff;border-top:0.5pt solid #000000;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:133%">44,366</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Income tax expense</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:right;text-indent:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">- </font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:right;text-indent:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</font></div></td><td colspan="3" style="padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:133%">-</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ccedff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt;text-indent:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Net income before noncontrolling interest</font></div></td><td colspan="3" style="background-color:#ccedff;border-top:0.5pt solid #000000;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:133%">47,676</font></td><td colspan="3" style="background-color:#ccedff;border-top:0.5pt solid #000000;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:133%">&#160;</font></td><td colspan="3" style="background-color:#ccedff;border-top:0.5pt solid #000000;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:133%">44,366</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt;text-indent:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Net loss attributable to noncontrolling interest, net of tax</font></div></td><td colspan="3" style="padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:133%">(999)</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:133%">-</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ccedff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt;text-indent:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Net income attributable to Arrowhead Pharmaceuticals, Inc.</font></div></td><td colspan="3" style="background-color:#ccedff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:133%">$            48,675</font></td><td colspan="3" style="background-color:#ccedff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:133%">&#160;</font></td><td colspan="3" style="background-color:#ccedff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:133%">$            44,366</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:2.5pt double #000000;padding:0 1pt"><div style="padding-left:2.75pt;padding-right:2.75pt;text-indent:10pt"><font><br></font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:2.5pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ccedff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt;text-indent:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Net income per share attributable to Arrowhead Pharmaceuticals, Inc. - Diluted</font></div></td><td colspan="3" style="background-color:#ccedff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:133%">$                0.45</font></td><td colspan="3" style="background-color:#ccedff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:133%">&#160;</font></td><td colspan="3" style="background-color:#ccedff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:133%">$                0.41</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt;text-indent:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Weighted-average shares used in calculating - Diluted</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:right;text-indent:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;108,143 </font></div></td><td colspan="3" style="padding:0 1pt"><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:right;text-indent:9pt"><font><br></font></div></td><td colspan="3" style="padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:133%">107,929</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"><div style="padding-left:2.75pt;padding-right:2.75pt;text-indent:10pt"><font><br></font></div></td><td colspan="3" style="padding:0 1pt"><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:right;text-indent:10pt"><font><br></font></div></td><td colspan="3" style="padding:0 1pt"><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:right;text-indent:10pt"><font><br></font></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt;text-indent:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%;text-decoration:underline">FINANCIAL&#160;POSITION&#160;SUMMARY</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:133%">March 31,<br>2023</font></td><td colspan="3" style="border-bottom:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">&#160;</font></td><td colspan="3" style="border-bottom:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:133%">September 30,<br>2022</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ccedff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:133%">&#160;</font></td><td colspan="9" style="background-color:#ccedff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:133%">(unaudited)</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt;text-indent:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cash, cash equivalents and restricted cash</font></div></td><td colspan="3" style="padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:133%">$          134,959</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:133%">$          108,005</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ccedff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt;text-indent:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Short-term investments</font></div></td><td colspan="3" style="background-color:#ccedff;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:133%">346,046</font></td><td colspan="3" style="background-color:#ccedff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:133%">&#160;</font></td><td colspan="3" style="background-color:#ccedff;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:133%">268,391</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt;text-indent:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Long-term investments</font></div></td><td colspan="3" style="padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:133%">78,834</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:133%">105,872</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ccedff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total cash resources (cash and investments)</font></div></td><td colspan="3" style="background-color:#ccedff;border-top:0.5pt solid #000000;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:133%">559,839</font></td><td colspan="3" style="background-color:#ccedff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:133%">&#160;</font></td><td colspan="3" style="background-color:#ccedff;border-top:0.5pt solid #000000;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:133%">482,268</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt;text-indent:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other assets</font></div></td><td colspan="3" style="padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:133%">331,469</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:133%">209,671</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ccedff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total Assets</font></div></td><td colspan="3" style="background-color:#ccedff;border-top:0.5pt solid #000000;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:133%">$          891,308</font></td><td colspan="3" style="background-color:#ccedff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:133%">&#160;</font></td><td colspan="3" style="background-color:#ccedff;border-top:0.5pt solid #000000;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:133%">$          691,939</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:2.5pt double #000000;padding:0 1pt"><div style="padding-left:2.75pt;padding-right:2.75pt;text-indent:20pt"><font><br></font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:2.5pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ccedff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt;text-indent:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Current deferred revenue</font></div></td><td colspan="3" style="background-color:#ccedff;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:133%">$            29,839</font></td><td colspan="3" style="background-color:#ccedff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:133%">&#160;</font></td><td colspan="3" style="background-color:#ccedff;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:133%">$            74,099</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt;text-indent:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Long-term deferred revenue</font></div></td><td colspan="3" style="padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:133%">1,075</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:133%">55,950</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ccedff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt;text-indent:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other liabilities</font></div></td><td colspan="3" style="background-color:#ccedff;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:133%">395,288</font></td><td colspan="3" style="background-color:#ccedff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:133%">&#160;</font></td><td colspan="3" style="background-color:#ccedff;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:133%">143,551</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total Liabilities</font></div></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:133%">$          426,202</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:133%">$          273,600</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ccedff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:133%">&#160;</font></td><td colspan="3" style="background-color:#ccedff;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:133%">&#160;</font></td><td colspan="3" style="background-color:#ccedff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:133%">&#160;</font></td><td colspan="3" style="background-color:#ccedff;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:133%">&#160;</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt;text-indent:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total Arrowhead Pharmaceuticals, Inc. Stockholders' Equity</font></div></td><td colspan="3" style="padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:133%">$          446,772</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:133%">$          398,520</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ccedff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Noncontrolling Interest</font></div></td><td colspan="3" style="background-color:#ccedff;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:133%">18,334</font></td><td colspan="3" style="background-color:#ccedff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:133%">&#160;</font></td><td colspan="3" style="background-color:#ccedff;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:133%">19,819</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt;text-indent:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total Noncontrolling Interest and Stockholders' Equity</font></div></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:133%">465,106</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:133%">418,339</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ccedff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt;text-indent:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total Liabilities, Noncontrolling Interest and Stockholders' Equity                                        </font></div></td><td colspan="3" style="background-color:#ccedff;border-top:0.5pt solid #000000;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:133%">$          891,308</font></td><td colspan="3" style="background-color:#ccedff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:133%">&#160;</font></td><td colspan="3" style="background-color:#ccedff;border-top:0.5pt solid #000000;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:133%">$        691,939</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:18pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:2.5pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:2.5pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ccedff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Shares Outstanding</font></div></td><td colspan="3" style="background-color:#ccedff;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:133%">106,869</font></td><td colspan="3" style="background-color:#ccedff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:133%">&#160;</font></td><td colspan="3" style="background-color:#ccedff;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:133%">105,960</font></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div><font><br></font></div><div><font style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:100%">About Arrowhead Pharmaceuticals</font><font style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> </font></div><div><font><br></font></div><div style="margin-bottom:12pt;margin-top:6pt"><font style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:174%">Arrowhead Pharmaceuticals develops medicines that treat intractable diseases by silencing the genes that cause them. Using a broad portfolio of RNA chemistries and efficient modes of delivery, Arrowhead therapies trigger the RNA interference mechanism to induce rapid, deep, and durable knockdown of target genes. RNA interference, or RNAi, is a mechanism present in living cells that inhibits the expression of a specific gene, thereby affecting the production of a specific protein. Arrowhead&#8217;s RNAi-based therapeutics leverage this natural pathway of gene silencing.</font></div><div style="margin-bottom:12pt;margin-top:6pt"><font style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:174%">For more information, please visit </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:174%">www.arrowheadpharma.com</font><font style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:174%">, or follow us on Twitter </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:174%">&#64;ArrowheadPharma</font><font style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:174%">. To be added to the Company's email list and receive news directly, please visit </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:174%;text-decoration:underline">http&#58;&#47;&#47;ir.arrowheadpharma.com&#47;email-alerts</font><font style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:174%">.</font></div><div style="margin-bottom:12pt;margin-top:6pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:174%">Safe Harbor Statement under the Private Securities Litigation Reform Act&#58;</font></div><div style="margin-bottom:12pt;margin-top:6pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">This news release contains forward-looking statements within the meaning of the &#34;safe harbor&#34; provisions of the Private Securities Litigation Reform Act of 1995. Any statements contained in this release except for historical information may be deemed to be forward-looking statements. Without limiting the generality of the foregoing, words such as &#8220;may,&#8221; &#8220;will,&#8221; &#8220;expect,&#8221; &#8220;believe,&#8221; &#8220;anticipate,&#8221; &#8220;hope,&#8221; &#8220;intend,&#8221; &#8220;plan,&#8221; &#8220;project,&#8221; &#8220;could,&#8221; &#8220;estimate,&#8221; &#8220;continue,&#8221; &#8220;target,&#8221; &#8220;forecast&#8221; or &#8220;continue&#8221; or the negative of these words or other variations thereof or comparable terminology are intended to identify such forward-looking statements. In addition, any statements that refer to projections of our future financial performance, trends in our business, expectations for our product pipeline or product candidates, including anticipated regulatory submissions and clinical program results, prospects or benefits of our collaborations with other companies, or other characterizations of future events or circumstances are forward-looking statements. These forward-looking statements include, but are not limited to, statements about the initiation, timing, progress and results of our preclinical studies and clinical trials, and our research and development programs&#59; our expectations regarding the potential benefits of the partnership, licensing and&#47;or collaboration arrangements and other strategic arrangements and transactions we have entered into or may enter into in the future&#59; our beliefs and expectations regarding milestone, royalty or other payments that could be due to or from third parties under existing agreements&#59; and our estimates regarding future revenues, research and development expenses, capital requirements and payments to third parties. These statements are based upon our current expectations and speak only as of the date hereof. Our actual results may differ materially and adversely from those expressed in any forward-looking statements as a result of numerous factors and uncertainties, including the impact of the ongoing COVID-19 pandemic on our business, the safety and efficacy of our product candidates, decisions of regulatory authorities and the timing thereof, the duration and impact of regulatory delays in our clinical programs, our ability to finance our operations, the likelihood and timing of the receipt of future milestone and licensing fees, the future success of our scientific studies, our ability to successfully develop and commercialize drug candidates, the timing for starting and completing clinical trials, rapid technological change in our markets, the enforcement of our intellectual property rights, and the other risks and uncertainties described in our most recent Annual Report on Form 10-K, subsequent Quarterly Reports on Form 10-Q and other documents filed with the Securities and Exchange Commission from time to time. We assume no obligation to update or revise forward-looking statements to reflect new events or circumstances.</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Contacts&#58;</font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Arrowhead Pharmaceuticals, Inc.</font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vince Anzalone, CFA</font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">626-304-3400</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">ir&#64;arrowheadpharma.com</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Investors&#58;</font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">LifeSci Advisors, LLC</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Brian Ritchie</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><br></font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">212-915-2578</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">britchie&#64;lifesciadvisors.com</font></div><div><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">www.lifesciadvisors.com</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Media&#58;</font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">LifeSci Communications, LLC</font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Jason Braco, Ph.D.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><br></font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">646-751-4361</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">jbraco&#64;lifescicomms.com</font></div><div><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">www.lifescicommunications.com</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Source&#58; </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Arrowhead Pharmaceuticals, Inc.</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%"># # #</font></div><div><font><br></font></div><div><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>3
<FILENAME>arwr-20230502.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2023 Workiva-->
<!--r:18e5b2ff-3fc7-4ce3-bcba-5f3605a5ad33,g:f131945f-82e3-4fa2-aa9b-762f5362ea7f-->
<xs:schema xmlns:xs="http://www.w3.org/2001/XMLSchema" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:arwr="http://www.arrowheadresearch.com/20230502" attributeFormDefault="unqualified" elementFormDefault="qualified" targetNamespace="http://www.arrowheadresearch.com/20230502">
  <xs:import namespace="http://www.w3.org/1999/xlink" schemaLocation="http://www.xbrl.org/2003/xlink-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/dei/2022" schemaLocation="https://xbrl.sec.gov/dei/2022/dei-2022.xsd"/>
  <xs:annotation>
    <xs:appinfo>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="arwr-20230502_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="arwr-20230502_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:type="simple"/>
      <link:roleType id="Cover" roleURI="http://www.arrowheadresearch.com/role/Cover">
        <link:definition>0000001 - Document - Cover</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xs:appinfo>
  </xs:annotation>
</xs:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>4
<FILENAME>arwr-20230502_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2023 Workiva-->
<!--r:18e5b2ff-3fc7-4ce3-bcba-5f3605a5ad33,g:f131945f-82e3-4fa2-aa9b-762f5362ea7f-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel"/>
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:label id="lab_dei_EntityCentralIndexKey_75d7b0c2-ee72-40f4-b2e5-66116df9e356_terseLabel_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:label id="lab_dei_EntityCentralIndexKey_label_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCentralIndexKey"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCentralIndexKey" xlink:to="lab_dei_EntityCentralIndexKey" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressAddressLine2_a5a5f299-d0d5-4134-ace6-5285d8468d9c_terseLabel_en-US" xlink:label="lab_dei_EntityAddressAddressLine2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line Two</link:label>
    <link:label id="lab_dei_EntityAddressAddressLine2_label_en-US" xlink:label="lab_dei_EntityAddressAddressLine2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine2" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine2"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine2" xlink:to="lab_dei_EntityAddressAddressLine2" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_e11a5377-3806-4362-9797-062eabbb24f0_terseLabel_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_label_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityTaxIdentificationNumber" xlink:to="lab_dei_EntityTaxIdentificationNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressAddressLine1_11afbf84-373e-4542-9f67-87c449cc1fe2_terseLabel_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:label id="lab_dei_EntityAddressAddressLine1_label_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine1" xlink:to="lab_dei_EntityAddressAddressLine1" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_TradingSymbol_e95b5b76-f9ec-467f-9e0c-5f2a714fcae3_terseLabel_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Symbol</link:label>
    <link:label id="lab_dei_TradingSymbol_label_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Symbol</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_TradingSymbol"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_TradingSymbol" xlink:to="lab_dei_TradingSymbol" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFileNumber_d58bff90-28fe-4a66-94e7-12345502caa8_terseLabel_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity File Number</link:label>
    <link:label id="lab_dei_EntityFileNumber_label_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity File Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFileNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFileNumber" xlink:to="lab_dei_EntityFileNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_PreCommencementIssuerTenderOffer_3e22d901-3f2c-4bd0-93ed-a0a720cc2900_terseLabel_en-US" xlink:label="lab_dei_PreCommencementIssuerTenderOffer" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pre-commencement Issuer Tender Offer</link:label>
    <link:label id="lab_dei_PreCommencementIssuerTenderOffer_label_en-US" xlink:label="lab_dei_PreCommencementIssuerTenderOffer" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pre-commencement Issuer Tender Offer</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_PreCommencementIssuerTenderOffer" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_PreCommencementIssuerTenderOffer"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_PreCommencementIssuerTenderOffer" xlink:to="lab_dei_PreCommencementIssuerTenderOffer" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_SolicitingMaterial_ac3dc504-eb24-4c72-993f-ac0b638a4ee3_terseLabel_en-US" xlink:label="lab_dei_SolicitingMaterial" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Soliciting Material</link:label>
    <link:label id="lab_dei_SolicitingMaterial_label_en-US" xlink:label="lab_dei_SolicitingMaterial" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Soliciting Material</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SolicitingMaterial" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SolicitingMaterial"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_SolicitingMaterial" xlink:to="lab_dei_SolicitingMaterial" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressCityOrTown_d1b2eae0-b901-4de0-844b-a0eeeb72cc09_terseLabel_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:label id="lab_dei_EntityAddressCityOrTown_label_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressCityOrTown"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressCityOrTown" xlink:to="lab_dei_EntityAddressCityOrTown" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_13002699-ab6b-471d-a04b-f0999e0e9f05_terseLabel_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_label_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityIncorporationStateCountryCode" xlink:to="lab_dei_EntityIncorporationStateCountryCode" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_LocalPhoneNumber_8ce8ee2c-2a69-42f8-9a51-b92ae5b2d07d_terseLabel_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Local Phone Number</link:label>
    <link:label id="lab_dei_LocalPhoneNumber_label_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Local Phone Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LocalPhoneNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_LocalPhoneNumber" xlink:to="lab_dei_LocalPhoneNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressPostalZipCode_dbf207a4-df75-4d65-a141-142b1a9ac11f_terseLabel_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:label id="lab_dei_EntityAddressPostalZipCode_label_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressPostalZipCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressPostalZipCode" xlink:to="lab_dei_EntityAddressPostalZipCode" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_WrittenCommunications_5bfbb0fa-a5d1-4b9f-81c2-ed914628db7a_terseLabel_en-US" xlink:label="lab_dei_WrittenCommunications" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Written Communications</link:label>
    <link:label id="lab_dei_WrittenCommunications_label_en-US" xlink:label="lab_dei_WrittenCommunications" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Written Communications</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_WrittenCommunications" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_WrittenCommunications"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_WrittenCommunications" xlink:to="lab_dei_WrittenCommunications" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CityAreaCode_87f2f6b9-eacf-4668-8493-b1093c595b5f_terseLabel_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">City Area Code</link:label>
    <link:label id="lab_dei_CityAreaCode_label_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">City Area Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CityAreaCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CityAreaCode" xlink:to="lab_dei_CityAreaCode" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CoverAbstract_label_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cover [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CoverAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CoverAbstract" xlink:to="lab_dei_CoverAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_Security12bTitle_56eed499-68cd-42d2-8e0c-ef29edd86091_terseLabel_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:label id="lab_dei_Security12bTitle_label_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_Security12bTitle"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_Security12bTitle" xlink:to="lab_dei_Security12bTitle" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentType_62b205ba-0ae3-4d47-a4c3-42a0af2e0d01_terseLabel_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Type</link:label>
    <link:label id="lab_dei_DocumentType_label_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Type</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentType"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentType" xlink:to="lab_dei_DocumentType" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AmendmentFlag_a1eccf1e-1aeb-4b88-8a52-9cec96ada24f_terseLabel_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment Flag</link:label>
    <link:label id="lab_dei_AmendmentFlag_label_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment Flag</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AmendmentFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AmendmentFlag" xlink:to="lab_dei_AmendmentFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_SecurityExchangeName_4536aeb4-1b60-4d9b-add7-4ca15fa41b48_terseLabel_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Security Exchange Name</link:label>
    <link:label id="lab_dei_SecurityExchangeName_label_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Security Exchange Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SecurityExchangeName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_SecurityExchangeName" xlink:to="lab_dei_SecurityExchangeName" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityRegistrantName_83f7575c-8718-481b-848e-8e34bed35263_terseLabel_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:label id="lab_dei_EntityRegistrantName_label_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityRegistrantName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityRegistrantName" xlink:to="lab_dei_EntityRegistrantName" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_f446966d-930f-4608-a66a-66b5c17a5b21_terseLabel_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_label_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityEmergingGrowthCompany" xlink:to="lab_dei_EntityEmergingGrowthCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressStateOrProvince_687052d2-0a56-4b47-9b82-8c224ef3688c_terseLabel_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:label id="lab_dei_EntityAddressStateOrProvince_label_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressStateOrProvince"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressStateOrProvince" xlink:to="lab_dei_EntityAddressStateOrProvince" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentPeriodEndDate_6617ba40-1939-4f88-a807-7d4a593022dd_terseLabel_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Period End Date</link:label>
    <link:label id="lab_dei_DocumentPeriodEndDate_label_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Period End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentPeriodEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentPeriodEndDate" xlink:to="lab_dei_DocumentPeriodEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_PreCommencementTenderOffer_cd2323db-0ad7-49a7-8fb4-d08d6f2ddc34_terseLabel_en-US" xlink:label="lab_dei_PreCommencementTenderOffer" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pre-commencement Tender Offer</link:label>
    <link:label id="lab_dei_PreCommencementTenderOffer_label_en-US" xlink:label="lab_dei_PreCommencementTenderOffer" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pre-commencement Tender Offer</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_PreCommencementTenderOffer" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_PreCommencementTenderOffer"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_PreCommencementTenderOffer" xlink:to="lab_dei_PreCommencementTenderOffer" xlink:type="arc" order="1"/>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>5
<FILENAME>arwr-20230502_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2023 Workiva-->
<!--r:18e5b2ff-3fc7-4ce3-bcba-5f3605a5ad33,g:f131945f-82e3-4fa2-aa9b-762f5362ea7f-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.arrowheadresearch.com/role/Cover" xlink:type="simple" xlink:href="arwr-20230502.xsd#Cover"/>
  <link:presentationLink xlink:role="http://www.arrowheadresearch.com/role/Cover" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract_c5407c3b-8d44-4046-9a5f-fde42f19d143" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CoverAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType_a8a8abc6-c6dd-45bc-92c4-b5ff5763e50d" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentType"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_c5407c3b-8d44-4046-9a5f-fde42f19d143" xlink:to="loc_dei_DocumentType_a8a8abc6-c6dd-45bc-92c4-b5ff5763e50d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate_ccb2bd11-e6b9-4841-aabd-cf21c9d549b3" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentPeriodEndDate"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_c5407c3b-8d44-4046-9a5f-fde42f19d143" xlink:to="loc_dei_DocumentPeriodEndDate_ccb2bd11-e6b9-4841-aabd-cf21c9d549b3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName_2adacee7-3ba7-4d49-bef3-e5429661cf6d" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityRegistrantName"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_c5407c3b-8d44-4046-9a5f-fde42f19d143" xlink:to="loc_dei_EntityRegistrantName_2adacee7-3ba7-4d49-bef3-e5429661cf6d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode_4e7f4c61-f94d-4ee7-9c02-0e62b0601794" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_c5407c3b-8d44-4046-9a5f-fde42f19d143" xlink:to="loc_dei_EntityIncorporationStateCountryCode_4e7f4c61-f94d-4ee7-9c02-0e62b0601794" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber_baa7f65f-13fd-41bc-a0d1-7bf35d82e853" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFileNumber"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_c5407c3b-8d44-4046-9a5f-fde42f19d143" xlink:to="loc_dei_EntityFileNumber_baa7f65f-13fd-41bc-a0d1-7bf35d82e853" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber_5767724c-acc0-418f-9068-d49da0422278" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_c5407c3b-8d44-4046-9a5f-fde42f19d143" xlink:to="loc_dei_EntityTaxIdentificationNumber_5767724c-acc0-418f-9068-d49da0422278" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1_180086b6-c905-4e8a-b9ff-464dd95732af" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine1"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_c5407c3b-8d44-4046-9a5f-fde42f19d143" xlink:to="loc_dei_EntityAddressAddressLine1_180086b6-c905-4e8a-b9ff-464dd95732af" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine2_d6cbc2e0-33e8-42a2-90b5-b8e5bb98ed6d" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine2"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_c5407c3b-8d44-4046-9a5f-fde42f19d143" xlink:to="loc_dei_EntityAddressAddressLine2_d6cbc2e0-33e8-42a2-90b5-b8e5bb98ed6d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown_042f3f8c-0ee9-4c2e-9d96-403b8cf6838f" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressCityOrTown"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_c5407c3b-8d44-4046-9a5f-fde42f19d143" xlink:to="loc_dei_EntityAddressCityOrTown_042f3f8c-0ee9-4c2e-9d96-403b8cf6838f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince_aaa09926-0cd4-44b4-afdb-99236b091df9" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressStateOrProvince"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_c5407c3b-8d44-4046-9a5f-fde42f19d143" xlink:to="loc_dei_EntityAddressStateOrProvince_aaa09926-0cd4-44b4-afdb-99236b091df9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode_b2140469-4f6f-48f9-bfb1-37804e77facf" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressPostalZipCode"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_c5407c3b-8d44-4046-9a5f-fde42f19d143" xlink:to="loc_dei_EntityAddressPostalZipCode_b2140469-4f6f-48f9-bfb1-37804e77facf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode_81931530-ea29-4d94-a68a-dc1e7104fff0" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CityAreaCode"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_c5407c3b-8d44-4046-9a5f-fde42f19d143" xlink:to="loc_dei_CityAreaCode_81931530-ea29-4d94-a68a-dc1e7104fff0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber_14519462-da31-4071-bd73-1213f68ee169" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LocalPhoneNumber"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_c5407c3b-8d44-4046-9a5f-fde42f19d143" xlink:to="loc_dei_LocalPhoneNumber_14519462-da31-4071-bd73-1213f68ee169" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_WrittenCommunications_83c556fd-00a7-47f7-9a93-4fd7fa078d6f" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_WrittenCommunications"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_c5407c3b-8d44-4046-9a5f-fde42f19d143" xlink:to="loc_dei_WrittenCommunications_83c556fd-00a7-47f7-9a93-4fd7fa078d6f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SolicitingMaterial_005c6507-5acf-4ad7-9e69-4ce8964966fb" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SolicitingMaterial"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_c5407c3b-8d44-4046-9a5f-fde42f19d143" xlink:to="loc_dei_SolicitingMaterial_005c6507-5acf-4ad7-9e69-4ce8964966fb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_PreCommencementTenderOffer_23b047fe-9ad2-4251-bfcb-727798731675" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_PreCommencementTenderOffer"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_c5407c3b-8d44-4046-9a5f-fde42f19d143" xlink:to="loc_dei_PreCommencementTenderOffer_23b047fe-9ad2-4251-bfcb-727798731675" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_PreCommencementIssuerTenderOffer_015fb6da-f70e-4ce1-956b-81ceec1e41d6" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_PreCommencementIssuerTenderOffer"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_c5407c3b-8d44-4046-9a5f-fde42f19d143" xlink:to="loc_dei_PreCommencementIssuerTenderOffer_015fb6da-f70e-4ce1-956b-81ceec1e41d6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle_1f3450fa-56d1-454e-bd86-ef81ae020bf3" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_Security12bTitle"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_c5407c3b-8d44-4046-9a5f-fde42f19d143" xlink:to="loc_dei_Security12bTitle_1f3450fa-56d1-454e-bd86-ef81ae020bf3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol_b67199d2-792a-41e7-a099-b0f91d06dec9" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_TradingSymbol"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_c5407c3b-8d44-4046-9a5f-fde42f19d143" xlink:to="loc_dei_TradingSymbol_b67199d2-792a-41e7-a099-b0f91d06dec9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName_29c6cbc3-84b3-4af3-aa03-df95132c80b4" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SecurityExchangeName"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_c5407c3b-8d44-4046-9a5f-fde42f19d143" xlink:to="loc_dei_SecurityExchangeName_29c6cbc3-84b3-4af3-aa03-df95132c80b4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany_508bd41e-f2bf-470e-b625-292bd1a72ee4" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_c5407c3b-8d44-4046-9a5f-fde42f19d143" xlink:to="loc_dei_EntityEmergingGrowthCompany_508bd41e-f2bf-470e-b625-292bd1a72ee4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey_10546ff3-90de-4f61-b2a7-ecc392de4144" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCentralIndexKey"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_c5407c3b-8d44-4046-9a5f-fde42f19d143" xlink:to="loc_dei_EntityCentralIndexKey_10546ff3-90de-4f61-b2a7-ecc392de4144" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag_14a16000-b1a6-4edb-9ba3-54d7d10ab748" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AmendmentFlag"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_c5407c3b-8d44-4046-9a5f-fde42f19d143" xlink:to="loc_dei_AmendmentFlag_14a16000-b1a6-4edb-9ba3-54d7d10ab748" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>6
<FILENAME>image_0a.jpg
<TEXT>
begin 644 image_0a.jpg
MB5!.1PT*&@H    -24A$4@  !(    &"" 8   "86+CV    "7!(67,  $SE
M  !,Y0%USO"5  $$-$E$051XG.R=AT,<R9GVOS_NTVKMW?5ZU[ZU?6O?G<]W
MYSO;=_;9Y^\LL2L&)+) ( F$)(2RA%#..>=$#@($B"1RSF'Z_?JMZC2Y9^AA
M L_/KAU$F.FJKJ[PU!O^#P$           " I.;_Q/H"             $!T
M@0 $            D.1   (           !(<B   0           "0Y$(
M            DAP(0             !)#@0@            @"0' A
M      ! D@,!"            "#)@0 $            D.1   (
M  !(<B   0           "0Y$(              DAP(0             !)
M#@0@            @"0' A            ! D@,!"            "#)@0 $
M            D.1   (           !(<B   0           "0Y$(
M        DAP(0             !)#@0@            @"0' A
M  ! D@,!"            "#)@0 $            D.1   (           !(
M<B   0           "0Y$(              DAP(0             !)#@0@
M            @"0' A            ! D@,!"            "#)@0 $
M        D.1   (           !(<B   0           "0Y$(
M    DAP(0             !)#@0@            @"0' A            !
MD@,!"            "#)@0 $            D.1   (           !(<B
M 0           "0Y$(              DAP(0             !)#@0@
M        @"0' A            ! D@,!"            "#)@0 $
M    D.1   (           !(<B   0           "0Y$(
MDAP(0             !)#@0@            @"0' A            ! D@,!
M"            "#)@0 $            D.1   (           !(<B   0
M         "0Y$(              DAP(0             !)#@0@
M    @"0' A            ! D@,!"            "#)@0 $
MD.1   (           !(<B   0           "0Y$(              DAP(
M0             !)#@0@            @"0' A            ! D@,!"
M         "#)@0 $            D.1   (           !(<B   0
M     "0Y$(              DAP(0             !)#@0@
M@"0' A            ! D@,!"            "#)@0 $;*)XO5J_KUA^HAC_
M(T46Q><]@N'V\V]%^QC/OU>T3_-WG8K^-P           (  !.PBA1FIPUC%
M($WH\1"!W&0*-V[SUW1A** R8_V90I[B$O]/%X?<EM_1OE),04BQBD
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M:>_#OU-%/\VKIS^6M5+^A6ZJ?#)(CYK&Z%W?+(U.+<$%#           T(
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M\L1/,2V#:NA_#K;1P\8QZAN;)STVCZ+HCG46-S$'@AU+ :C5KT"7R.7;'1"
M         " 60 !*!HPP-=+^9'9AF>[4CM&?RUOHR\Q:3<A@\:?*DM&KEL))
MK[X>B[1:J1664I^(N$<U]'E&+?UN[SLZ]620AJ:61*P>Q;@!;DMVM=4! 0@
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M7W^24T_%UWJH=V3>-RR3GW\%LQ(R@T G0ZRF*D/(^G9' P0@    (*8@$R<
M(/E853*>=30L0@"*6[0.[*$DR.^Y%3=U#\_1[FN]]-/<>OK40ZCPG]D+);IE
M0[H,&/V#]!KZIYU-=.KI((U.+1I!HOD^ZI9!BL@G9KFM?I "T'OM?DH1)=9U
MC+AMN ZN6N%.!PL@    (#I<OWB.RHJ+Z$!)$94%*0?V[*(/G1VQOEP  '"4
MX>$A.GZH+.CXIY?SE2=I:FHRUI<<$R  Q2V*4<RX,@K-+;CI:M4P_7I7LW!-
M^B3=VT(D<86"1"Z&2YAF9?4#];[\U_Y6>MDV*2RUC.Q@1I!HMWF;_< "T%\.
MMI%PUW,E]CW]OVFZ*%E%_U#42!_'(  !    3G/RT '*VI)"6:F;*3-U$V6K
MK_QUELNSY*1]1ZW-C;&^7   <)2!CQ]IU_8LGS'/7RDOW4T3XV.QON28  $H
M3I%:@:+I!6Y:7'%3?=<,_?7P>_H\4[I[L4O7!A_!!]8_L2@RJYJ\%QM%["#Y
M_:^RZRCO?#?UC2Z(>ZD+00HI5FG/!UT VNAEW96(Q8R75$/_6=9*(]/+:_@D
M 0   .N#DX?+I."CBS[J:[:?DI.60JWOFF)]N0  X"@#'WMI=UZ6WW'/NQP4
M M!HK"\Y)D  BF<413@,S2^M4,7C0?I%08,4!$3\&3T6C57PX:]K8[[A7Y=%
MO0^?NK0802X]VYKY\]_O:Z'G+6QF*.^I=H,#2D"C4TOT[Z7O-*$OL44]:QRE
M/QUHH;'II35[A    (#U@A2 4LQ3[E3_(I"T (( ! !( BQ;*1: V +(C@!4
M7KH+ A"(+;XR@$)NMR*L?GC3S+%EK&+/1HNUB6_,G\1V&4K4LD%K^PV:^,/W
M:X,E^/8/M]92^9U^8=UCQG?R+P -3BS2+PN;Y'LGN #$11>!_EC>0J,0@
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M!!!#3CP:E**/Z#.)G09^@W;M/\ZIHP]#<Y8G!     !. 0$( +">@0!D#PA
M#F&UY6##CI>M$_1CS?*'-[\;TR'^H'"IHHHG@Q1* )$"D!1_-KH26P#2+=^^
MSJFCOK&%D'4'    0/A   ( K&<@ -D# I!C:!*0^O^6OEGZ37&SYR8XO08B
M$(JPAKGR>LCL+P'$D++;'\7O;TS3X_\D;M_1LYE]DU=/LXONH/4&    0&1
M  ( K&<@ -D# I!#Z F]^T;GZ9]V-M&G%G<OB#\H9JFERT( ,GN./[+/=9&T
M_JFF1!9_9)&63#_;7BO-X[1G!0    #. 0$( +">@0!D#PA 3J'N:$>FELA5
MV4$;T^7&5Q=^(/Z@6,O+UDF+ !)  #K;21M=M4;\G$0. JV[@/UZ=PO!^@<
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M[-[E8WHK3@#9(L&A4S"?"=KS1$Q?Q/ "J61''CU[_"#D9G=N=DX(&W8_TT,
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M;9UUMT(A?$TY<TJ0S#0VU!E"@QTW'L_%^7?TX,X-=0(;];NH#OP=[?LVQ:)
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M :PF @C2G *<+0'GYWV#X:XU/3W=='#O;AON1U[/7EH*W;IV40N0;^W5JQ,
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MWW\")H#(./KO\CZ==F2M\6%VDX:*40^@Y=CP !*A1P I%V9\?^',*2H(&XW
MC4K8BD K#%0D5*8FM,1APP_>>0#%"=<6!^_?L'">4&OJO'[Q3(K3]R2>^_CA
M@Y#7-WA@GK:XV2_*3M=M![&=2@+T *)G)><\7W%215ZXG9^(4?*HX9Y?]Z"Z
MJ@+,4O_3O\]8G_6--7^69'9-BG];W[UFND-NYENE^#B&PZ$VF;)MO#E;5X=5
M3ITMD$IN/9Q(7^_I:G>NK.'@!)#O!!#>;XD \D#B>=26BI'2;FD&KP@@3'WN
M:8X72B3U1W] "2"/)*,_!)#=*P)([-O/'S^,PO54OI[AH4&O^S$G@*(:XI:
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M<N=FG=R>Q_0-@IH+9ST?5/'@:'-]#3*/)^C.*<JL4@_OW:':2^)Q@O4$GA-
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MX?BY>.:T;#0ZD3_./U>?/\,($O6R&1"0-)"R@26X]Z["ZR[*-%-"3'</I2"
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MXF02B)2>SG;/!XTHR..AK?6]UXMS* @@-'0OG:V$S0C9(/E* ,W/S7H^Z#X
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M3=<;6]BF_?-C(521A8#%'@$T/CJL?@JFLQ' M,26YG?2=Z-A@4;@->%3=DX
M&0=?":"],!)31JTK,<VXNR=V(@%4FI=#Q=2C$<\?-TIBQ7KI@;$=SI:7P-JJ
ML?H-J$]S]>(Y#X:U\/,Q]'YHTCT6BD6;31Z,'>%O)W(S@ZZ/T]71IF]\)<1)
M?SM57$#:UWVZ^Z'^/N;1<$R\5Z[]5B*WDHY .]4VVK\)G!- _A- ?=U=D(%"
MNCJAM.(\FI>9!JLK>ME/.1!(?ERJJO!,? AC\-SID["VYG[\12)0$+_J5*FK
MY[=FF_A!  F"IH\;[WN]KRK)R8*IR3%9"S5(60GW#0Z@7O-T[?'"DY430)P
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MX(:/V0"1R(-]E*! $7H5Z:-# *%P+4MWSRHW.3%.QYE7<QAI&]0]"47\+B>
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MY&8CBV%K]V[=@)6EA; *&?(66.<73YJ\"I$2#2_<A.^&N?>/"!1JS4]/\8(
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MYX475H30+=(_4Z\-P_K.GD[WEKUO7O4NPT\RV_>MCK\OZX&%U5WA[#P,+%*
M!)!9(("4A1- '!P<T0 CI,R>-C6JR!^SZ#4I_LX4#V,CPX&?*,:A2P!E< *(
M@X.#0PN< /((=<@,QG2W#:_!YRF, #H0<F.?%UY<R\%$*_Q+;CL,S6R"DN;1
M[-_D_\UM&_RYHE<0?=Z/.EK@Q])>6%S=4XTSCO ')X X.#BB$;L[.["QOB:4
M=:&P]S:;]]XZN)K=N5Y+YTE- D@HO=V=P;N8& $G@#@X.#A\!R> /(!FM5'D
M/!;#90KJQVDH&(K9[I_1S LOWA5,X7[CS2S8[*)GC3N"!4,;'7#]S=P^AS.V
MT+3TJ$VDTB+B"'MP HB#@R,:T=;Z'LY7E,'YTR?)ZTDX1U_+H+JJ$J8FQKP^
M#JYDKY\]E772% 2060@#PSET:G(B>!<3(^ $$ <'!X?OX 20%W"(0K6*%-HS
MR[OPU\I^8L@V2QF7>.$E' IZIIEK1V!CQZ[P7W-#KI"^W3FZ#K\M[-IW(O/W
MI;TPM[HK<JN<_HD0< *(@X,C&O'\T4-)VRSMF.BY$P?9J288&NSSZ5C34Q-0
M6I##CF<2O7_$$+ CE&"RVWGH<Z#@!! '!P>'[^ $D%]@HM#O!U?@TV269IL9
MM18:$L:%H7G9SW(@B176[UK@-P5=,#2]J>JKPCO%O^QUUV:'(Q<'V+&24,LJ
M.!F_M,J_%G;"R.R67$^.B  G@#@X.*(1SQ\K""#!2P=_SDY-A*'!?I^.A5DW
M.]LLD&L^SKR CL5)QSY=>@*FQKWW*.)P#TX <7!P</@.3@#Y 5$/R&9WP(4G
MT_#Y<2LUOJDP-"UHX'*O(%[VH[3(V>A,%O@JS0K/NI>IUYJ4P4Y19$USS/KE
M@-HWL_#)<=9710)IO^K^Z_Q.Z)O<$ :5,AT\1SB#$T <'!S1"(D $@@$\3T2
M0!]\)( 02 (M+<[#J^=/X6KU!;A^[3*TO'L#FQOKP-<[8\ )( X.#@[?P0D@
M/^"0XE4<L+2Q"_\X-R ;SR8+UP3B99\+>NVT4#VJ@MMCU*N']E+G5"8._+V<
M=KU_:@-^4]!!^RX-8\3,8?O8=[_/ZX3^24X81!HX <3!P1&-,)H DJ%\$,-A
M)#@!Q,'!P>$[. 'D-\2L8'88F]N&'PJ[%!G!. '$RWX7"QRY. B+:[L*SQ]@
MGC5(_#A SFU+7M>W;/3SM*^:9"^B_<QJ]WU^!PQ,KHNCB>^-(P2< .+@X(A&
M&$D N3R X0@*. '$P<'!X3LX >0/'.J@&KO= 4UMB_!->CLU;+D'$"_[5S!D
MRP(_R^P0='^<GS0*!!#]V4[)GUV[':Z\G('/4YA^U4$D@,AQ]I/\P?(ON9W0
M.:8@@#@#%!'@!! '!T<T(G@>0!S! B> .#@X.'P')X "A:"U@O^=?S)#1:&=
M-8 .FC@AQ(L11=3JD47',>/7U^9VN-<Z#VH"1>.]\$32.KP*WV:V2<=EQ[/L
M.P'T=7H;O.Y;!EF2FD.?!/.EE3Q]UO]P!$X <80G IE%G+\;JADI&F?"8%Q3
MH,?4_KZK"#3+WI63:@J8 '(](P\)0P3: IP XN#@X/ =G  R"&C"KFSN0?:-
M$?A8,LY%P[J%&-G[)Z[+2W06VH],+1)A@UX['R>UPNG&2=C9M8%2Z-GA0@#9
MJ4OZ]-(._/%T'SM&B(G);\QM\*9O)23C-?SA*N"M;:0Z_\[N)9WF_[;;" +(
M.3PB<LP@ZO,)3$O+'UT/3_=4CM34_HY=[X.*SXLO/M0OJ#<A='=8V=?8.[OJ
M;VKO0^6KYWME/%Q'KT/C=\:<2?F#\_7[\%V_SVYDVP9RO^3//GO\4$C3+I)
M\?1]3HI(  52;_6#&&/@Q_TRJ"L[3R\>#^EP>/B0?VUK% 'D=DV2JN+MA7)P
M<'"$/S@!9"!PFS:WN@/_6]Y+-5547D")/#2,%R.*1<XXE\1T?S:V;>H-BACV
MY0 I&YB8]2OO]AA\FBR2DZ$E)7]"":#E$([82(5(/KC">=LL;FJ-U*/0)8 V
MO?< <C4YC=]92^?P\?KU/A^\_;^3 2+>.XUS.G2SYGGGS:*R:QSZG_4',KFB
M>_9]A5MN38(PMD)MY.E8[,:-9=>1Y^G( 7<3H]O5A^.Y;S<G LB92, T\"G^
M>P#MJQ90B+A>AT#N:%ZK"V]B[-@W@@#2OD=N""&OO\_!P<$1ON $D&&0GR1B
M:NO?E_90 UOVUA#3;//"BW]%3M/.LLW][^E>&)W; I ,+;OT7OS7+I _-IL#
M[C8OP*="RO<#IM#W1PQ=>]FSHAQ"L0O5)ME#0V@\B-S>VH*%N3F8GIP0RCA]
M75E>@IV=;;?'\ <>"2"G8^/F>&UM%69GIA7UFX#YV1E8)[]WMWD.QJ;:;K/#
MVNH*K<L4J8-8\&?\O=TF>])IU,CP^N@=%^_;_.RLJLWP'F]N;-#D QZ/YG X
M78D\,XA_%QD@N]T&&^MKTCV:HN>;A'EROFTGKRYOR#&LX\+\G'"<<?HZ,S4%
MRTN+L+>W!\Y^-X9 HUXV<EUX7^=F9J2ZX/7-3$_!ZLH*F1=MZE;Q[,808+U=
MO[FSLTO;!>LT[51'_/WV]G80#4R6+7*=W/OYN5EZSY7C G^']]+N\+9]O#MG
MJ.%0>#PIQX=( "GG-4D#:*#/CQ-)_RA^90P!HGRX@\?#<;JTN C34_(]G!;F
MMI659=C=VS7DO.I*R(?$L81C2IQ;Q3EKCLZMJ_3OP4"P0\#VR/'Q&#-3$ZJY
M<7%AGGJ\<O*'@X,C$L$)((,@NVG;Z6:I>6@-?I+1IO#ZX2%@O 1>T','B1L4
M4&X;7@>U0>(0*!^Y5XI&4<?H.OPJKU/P3&/"T:'.5O=)4BLT6.;W=Z"&*X2;
MMK.S ^W65GCU_(E+:6U^!Y)W OV\'1;G9^'IHX=0<_$<G"S*A<*L-"C,3"4E
MC98S)T_ M>IS\/K%4UA=7@(C# !O0\"0I!@=_@!-#^[ ^<J34)R;*=>/O)86
M9,.%RG)HNG\7QD:'#:F;.^R0>G60=KU]HP[.GRJ%$JR+T$98EY+<##AWN@3N
MW*B%GLX.V-NS"=? VGMF>AK>O'PNW(NGTCUY^_HE)=D\PT$]"+3N*Y:MK0V%
MMY(=AHBQ>>/:%=)&.4*;L7J>+,R#ZK.5\*CA/C7V-,]$ZMS3U0&OG>HJ%B60
M^)D8&X'&>_5PD=R+DCS6+@5"VYPLS(&K%\["RV>/86MCW>-5+I.V>/'L*5RJ
MJH3RHCRIW@7DGA=EIT-E:1'<KJN!=DL+,=PTB,D H#3$=K:WH*O=2N[G-3A?
M44:N*TN^WZ04YV1 %>D'M^NNT<_MB741#C$Q/JIYG]Z\? 9+2PL:GE.^U=-A
M=Q #<HZ,RV=0>_D"':?R^&#E!&FO"M)>5\GX??[D(25C](@_'VL!=ML>#/;W
M0L/=>KA QB[>:V4;B?>_NJH"'MRY#<-# V"C)(+OYQ*QM;GA=@S((5;>'P_?
M]W9W:,^7[]_"QL::YM>1A.SN;&>???&4C9-G3TB_K5 )0(L$4$;R,3HW:)UG
M@+2ANWJ/#@\K/OM4&H_OR+RQO.0_,2'V=;O=#I.3$_"DJ0&N7#@#%24%4)1E
MEL8O%ISKSI:70EW-)6AY]YK,5XN&DA;;VYMT/-\B8^D<SJW*L9;%SG_^]$FH
M)^W7U]M-VE[=AR8FQC7G*2S>S*U&$T!BV^!:AFLQMMOITD(R?YGEM95<UZGB
M?+A\GLS%C?=A:F+,P+')P<'!$7QP LA J)XED47DH741OLUJ9R$[3B%AK/"0
M,%Y\*:R__"*;;'A[G8UYUPV=^&1[=GD'?E/0!:)N$.N+X5'NM,R#WY94%&)]
M;848IF5@-L6[%#2HV1-[.\S-SL#U*Y=H: +]NT*XE.I64.V*>$A-B&/&C F%
M3).@ONXJ]3 (Q !0$4 F62SU@D  H5$R-- +->?/@#GQ"/N,J*EA8M]1$DC4
MP#I^#*K/5<+8R+!!Q@GS;,"GM,\?-Y$ZFTE=L!WC- T%4>N#UB\1VSH7WK]Y
M18T;A*7Y'621.IJ%MDP7[DFN^3B,# UZ59\'=VYIWM<T<CXD\A#8?DT-=R$=
MVTT2H57756SW!G(\+:,#29TK%\^ISB'6%^\';1MRCT:(05]SX2RD)QU5G<?E
MG*0/X?D*B0'TAAC+>[L[+N=<(_WV2=-#ZBE!KPF_D\#NL]P?%><@]2@FAB(C
M@OPA%;2QM#A/B2\DF[ -\5SB&%#50Y'A">]W64$.)?A$(@Z/H76OLLAX&^SO
M\;M^:/SV$R.XYD(59!Y/8&WEW \3G']WF-Z_S.,F<E^KX,- /R4P_ 5Z1+U]
M]8*VO]A&4ELXUT<B0N+H9\L*R;AX^QHVO2 #M8#C,4VC7;'@^/!G';AV^8+F
M\?">HA>5%K:VMN RN0?.XT/6_E&/ 5$,6NL\2&RX\QA\VM1 /G-$'G_"W)>7
MGN)G2!E;*]$KJ[/-"I4EA9"1?%28AS7ZCG+N36#W-S,E$1[4WX3Q $AWG%N1
M6&EZ<!?R,E))WXBG?41J+R6!YC2W(OG:UMH"FYLL:RD^G, VTFK;82_F5J,)
MH,WU=6A^\YK4,Y.M7])UQ,ESB4(C"J\U/?$H68^K80K75M +?>7@X. (#W "
M*(C8M3G@VLM9^"2995@Z2$/"6.C- <$0W^_,2[Q$1J&BX29!ZT<*(6R!+U(L
M</7%##'RO%%M<,#R^BZ8:T="?CW:I07N-L^KZAOKP) H]$S0VLRB]P=Z%_;W
M=$+YB7S5)EM*78P;U 0GDD,PQD4C (_33(PXF\W9B/2N_9T)()$$0@((PX@L
M+>^AD!C@SH2".T)#N:$NS<^!SG8K)9$" 9(@:&B?*BZ@FW-U&SG5Q;F]A#KC
M4_];=5=A=769$D"9Y&>S\IK(:ZXYB7I&>(,'=VYJ7S<I:!BC486>.$@,J(P,
M%3D0)Q "1^#-BV=NKMU.B0+GNHK7;7?8*?&"A(YX[%3AN*DN?4?=MS*3CL'3
M1XU26"$-'R)]MH:<+R/IJ&N[:AA.XKG,Q^(H*?FTJ9&&601VO^W46#R-!K&B
M'F8W]U<M],L^@_WDQK7+L+2T2+U!M.Y39DH"]9KQ!*V1A!YX]^MO08[YN%PO
M>D^=QJ^RG4SJOHIC+2\C!1KOWX$-TN[>CEGJ=43N^\38*)P[?5)%^IDUVT-K
M;A':X'@B)1AGIB=E E(CU$D+C #2'@,X/OP!>E!I'0\]#&<]$$"N<R4IQV0"
MW85 T2CUUZ^YO?8G#QM<R&X\=IXY&88&] @@;?T9O(_S<S-P^?Q9R#INTKQN
M]<. PS(!K_Q,8CR<R,F MZ^>2R2WUGFU@'-K=WL;G#E90OJH<_]5O'<SQ^/?
MLU,2X?K5&M@AYT:RU1UQM;\$D -65Y9)?[I$VC9!(*_5:U:J,)>YK&4"N59"
MUJ_)\3$>%L;!P1'VX 104.& W3T[7'H^#8=2K* *NT$O#).%IXCGQ6TYD-0B
M$(0L[.O3)"M<>3E+^Y2G#3?^Q4:,HI,/)N$3\KU0Z_UH%PO<:9ECS\OX?HE"
MCP!"<J2CO95Z_3@;:II&N\+C1DG&B']KO'L+-J0G^4[Z,#H0"2!GHQ%#P%X^
M?019*4D*CP_1R%4:4VZ>4@L&%QJGW5WM4OB5]Q#"(FQVZI9/#23G3;Q(/C@]
MF5:V(]O@"W4^=A@NG:V YT\:(3/9Q'YO- %$CH5Z.6W65OHT7WF?7#V[V"L:
M*"-NSJM- #&#%OL"DC\Y:<ENGVP[&S;,(%88P(E':4@8 KU)+I+V,2O(*2V#
M4UE2)6(HGAX;OXO:*SY[M0CD U[OBZ>/J5&9YM1FRK$A7J_S4WSGSU>=.@GW
MZV\$1  )%031$PV]+4KSLUG;'(MS)2,UC'CZ&?&SY%4L8M^M+"NBFB3>#!(D
M:C#L*$\DG\1QF'!8ZM.TCR0H[H]),<:E]I(]N_(S4J"_M\<G8S<\"" '];2K
MN7#&A<RA;4S[1YPT-E3SE@:Y@6&&4A"V4UOX3P"Y ONYM;49\NG\&^=Q'E61
M5V[F'2RUU1=@60HG=:?'QEY19^C%DT?,0]&D:!^A3SJO12JRQ&E^P>]?/'L:
M&L@Z%'("B%S?TM(2G*LHI_=>GFN5;>JZYHE$H?@P!M>+XIPL&OK,P<'!$<[@
M!%!0P0RJK1T[5#V:@L]3,/6V* S--($.<&T@7C2**/A\4.@?GQVW0-[M4=*7
MO!%2Q(Q?=KC];@Z^,K<)QPPWHM%"KZWJT:2'C$:Q!3T""(W/DKQL%?GC_!F7
MI_9*(].)&$(/E]MU5P517H1W]T$B@$PR@8#'/)&;04,;E!MDLTM=G3?6VH8)
MAKNAKH*O0&, ]20P7"M-:7BY:1=G[RB5D2*\IB<=@:+L-"DL*Q@$T.CP$#$^
M3CH9%NIZ*>N9G9KD5A]#BP"2O<7BX$1>IHMAF*H@QES:Z)BZ#EC0>VAR8A0>
MWJNGX1O*-M$DDMP8G^)[#-D:]C$DAF8V)/?[[>L7-/3,I;^Y7(OZ&E5$D$!R
MT7 .<CVY:<D&$$",$,#/8^B4RJATZD=FC393]EM*_)CBU?>(DE4E,#<SI=)]
M<Q[!*&S>UOR.]AEG<E@]1\2KS^GTWL60)P5UB_JZ.[UNC_ @@%BH)?, 8F,M
M51&J*(T5DS9!K$T :<,H @@%E%N;W[+Y5>$YIE4?E_OK80SBO':M^KSB88";
M.I!U CT4)<\C#5+'[5JD_-NQ.&G,(=E?D)7JMH[[10"A5Q-J864D'M5L,Y'T
MU)I'U/,+^]N%,Z=I>W%P<'"$*S@!M$_8)(9[Z?UQ.)AL!3D[6*L@RLL++\Y%
M)@G12ZSXW@2L;>T)3^(<0H8?]\;ZZ]X5^'E6!_F^50@_#/7UN%X?CH&3#9-@
MMWOK>Q+]T". Y*?2HD$2Y[3)CA>,F2.@"F%PWHA+Q@[;_*.NBYRAQ0<"2+$!
M%KU,-)_T2AMFV<C6#KN2/4/^?WOGX1W%FN;G?\YWN#/K'<\FKW=VO6/[;)AS
MO,?>L^.U!\05C0 A(1 BB1QTR3GGG$$"!7+.*"%01KE?U_M5K@[J;D6:Y[GG
MN]UJNJNKOE!=[Z_>H,\/[MF1T?X$N5MSRQ%_9DG(X"Z,"#W>OMD>*,5.7Q5'
M[FA'#<")$("T/S0,2D.0$D0"KS\"!NH<V_!.U3=)/8"\OOUC0+ I"(@@[O9G
M6WT1-AP30AT<XU@]4(Q0,B=\IS\T'PM3>RFXVW7#2+9O6B=V&?;,J:NI-GEY
M$CS-@L<<&,_B@-=1:$P+4QA[8Q2 FIL^FE ;=_^*O7F5N#9]K[- WJ30&!3X
MQ^7TH88XJG=1J+*;_<3;AR</[\FRT@61<8P8L7-L47'+NDK99HV#MBWK*QUA
M+2BDS@R$"]JOK2HOS3C,9CH(0.:FG I VZH":R,P5V*S$OI?CW7!G.AXV>V$
MR0&4G#$)0)X#9-PDK Z*G-Y\2"'L^/,IM7#EO=>:1SNK-J9-N*P"26W-;2/^
M^,<2%$02YY-W/G%_CZ+G$Z?OW=^QJ12 -.G[TI)Y7K^61(Y'A2I=:T?V[[*^
M:[?LWKK)>?_,\.^&T_3FRK,GCT;]7@" J0(!:$()7XSU] ]+V<&W\LL%#<;[
MX8>D7AEX!-'\W%"_G%\O/^UX)=U?AP+7],GR__@NZ%KQZW^L?&QO(^;.I^GF
M 62W]6>""8D1@=(*0(X0X!O.LTR22C7 =OZ\42Z</B'7KUPP85CG3AXSN3XT
M3$/S/40OSH,7X?H>34B::>\G> #%PD:&EQ<H9N<KV;1FE9P\<E"N73HO-RY?
M,%55UJ^J,)XUX>/S0T]T>XL7S)76EL8,]RINRO1J7Q3'?*$D:*AZHDWI/)-#
MZ=310Z:ZTG6KOS19JPI.:RVCL4P%).\89@;Z/B**C), I-M<O6R)9R3I_BXM
MG2^[JC9)7<TM,S8?WK\UN9'4H-RTME(.6'V8BN0"4-"H=<*U"F>9O$9KEBV6
MO=M_EDMG3YFY<]+JETUK5MBAAH$Q#0M[2;PCYMC>4JN6EIKPFBOGSYCY>.+P
M/JDR8D(L8F2'MZ6A98V6(>:.9]K1MLX9+8V-IFJ9+4I$O%<"(J,::AM6+??F
MH([WM4OGC->#5KDR.9?FS P8?ZF-YFP$(,V'I?T:%+N2>6<LMOI%JS?I_-/^
MUSZ[:3T>W;?'&)WE$>\F?=0\1WNV59GR]M[Y,TF7=5O[X,^M8#BDO=8TY'"C
M]1T-=ZNEK;7%.O]T&T\0;5H:7BN5W;QZR50I"R7V+?37EA[',<L [^_[FK@#
M$::# &3?/XE+9V>[R:?SZ5.KJ;#6UMHJIT\<#<T!M^FYJ*&VQGY?I&D"].CV
M7<9# -*$_QM6KPBMX62>>A6+YIMQ4H\DG3\W+EMSZ=(%V;?3F><+YH3[2$4_
M:XWKNC#'D":43P42K7SE"\!1#QA;U"RWSH<J#&M>)'LN7[3ZX(SLM_9!0R!5
M&/'/GX%0T!1S8C($()T+6DFS=*X;QAI(6FT=D^8Z>OWBF0EW'1P8L+YO0/J^
M?I7&C^]-M<.2(M\#LB30/Z>.'S8W5KBJ 8#I" +0)-/1.R2;+S0%C& GR:^3
M\/<7SO.I-LQID]EJQ1/^O+&W\_[,V?5*6CL'(N7=@[B>0"/F>5/[@/Q^S9-I
M<$SIFYT(O4[6G]40L&'O3N?W3GH!R#>\M)5;1H0F@VUI:@QX\/AHZ(>*!\<.
M[K4,\T+O<YY(XUU\%YAJ4(E)H9,3%(!2M;)Y<RS#;)N\LKZ_OZ\O81O=G9W6
M1??90$A#$H\@ZX+\TKE37HA@\K17]@O]_7UR>-]N+TS&%VS\.[GJ8:-EGI\_
M>RQ?O_8F/38MS:R&WNIEBQ,,DXGT  IZ_IBPFB>/$LHEN_3W]4M;6UO2?U.2
M"T %_G@[_;)L<8DQT+1R5K2:F%;HJ;U]4Y99!E1Q*D^RX+R<4V#FV*5SIZWY
M^"%AH#1I=-V=VTZ_IIXWE\^=36N(NJC1=^S0/BD-])T[WNYQJW>;YJ5Z^OAA
M2G&BJ^.+\1I;MS(0HA6;F;0:5K8"4,W-ZW:5+;-NPYY=[EALW;A6[M772G^*
M^:AES!\_:##'87L;V&$S9RSCLL<D@4Y!/&[6_^6+Y^P*5*[(YHYCS%X/*HAU
M=W6,>BQ=UGH]>F"/+"KR0RL7!OI>O5.>/GK@?'=P-\)C.2T$H#1H?R1X,<;L
MX\NE:E>N I#KZ:MY_(X?W.^,H3UNQ0$O++/NK'$\L'.;O'SV)&5%O8XOGZ7^
M3K4USRN\^:=5Y>[<NBX#_8GG9WLG[ <]#QW8L\-?MQ$QW B!SF_($VL.#/3W
M)VQ*STFZ#S76]]EK;68X-]T4"D#Z^2/[=WOKPA?:9LKRLF(C\J5"$\9K.?BH
M$*Y-\QNI" P ,!U! )ILK!]5S<_R\Z5F^<W"!OE%D6WL:ZB.:_A/M7%.FVPQ
MQ!;^9L1J3>)G%4>T<EQL]ROYTCTHOLB3O-2L^_#A<[_\V^9G7MZ@:=T<H6O!
MWC?612Y)H%W2"T!N<N+9LL&ZD-?0CY$DPD^T,_6NY=V::F/P!X66DL %KR8%
MUH2NF9!6 #+;*I)[=7=-?I9TPZI&P8MG3TTI]50>%SNJM+)8CP3G>3*T%'N9
M&YX0$2;4<-8[W;>N77&$@-&]2[Y\:9.CEN%ERA-'$R2/LP 4%.;6+E\J[]^^
M'G4?TY'* RAHG&A"\<:/'[QJ:Z%O<XQVK1:F1KV;.#AY*W#Z8;X)$;'O>"?9
M][B=B+BYJ=&$(RT,&K*!OM#<&9D83>HIM-CU4)HS.R3\V9X-<^7*I0NFVE/"
M\45W3;U!.K[(J:,';<&F,/E<S$8 TFI"JY>7>^LMY#U66&"\>JY=/&>$R-&2
M*.N_JX!V]N0Q66-ML[;FEO%"& WU#EI=L3@@.A7XZ\'Z_NJ;-SS1-Z-]Z!^0
M<Z=.F+XN]L2R L\C:/?6J@0A,0H"4&8"D(N6%2\QH:$S0^<)][GFXFJX6V/F
MPVAG#+MT>YL1RC>N7FER-V52;?'9XT=>TGB[7\))X9>5SC?5Q#2L+G$>1:J9
M6?^NY_.].[<9;Z!0.-@4"4#J[;8]E']MEC>W=UIS>C1J;ER3S6M7RQ:G;5Y;
M:3RQ-+]>;T\:D18 8 I! )ILG-_#K_TCLN5BD[B5P4R>%J<L_/3+UT*;R#9C
MKEWBW:X(9WO^%.UY(Y\Z;?$G$UMP8&A$?MKU4GXL<JO-3?UQ9=)^O_J)$413
M"US?%Z.'@&F5D3)Y_^:54]HYL^VJ8:;A1,G"KFS1I$".'SZ0TNLD2#H!2*M3
M:0A+)H:%\5NSWJ=>(QK*YHH"P>U55I2EO0/K')QEO!_VO9J"PHJ&.<TO-(9=
MLF-+9_BJ8:!A0B5.E9=@>-&X>@!Y>6L*Y'[=W81]RK:D<-(DT '#4863!PVU
M:;=AYI8^6MLZ=>RP?^R%T;Q3=CM_ZIBUCH="GX]LT7M=*XBYU<ZB8[YV>;D)
M>1F-\Z=/AD+;O+##.79XE,XI%3Y'P_4MTT?UA#BT=Y=) CW6$+"&VCLFO"XZ
M!L83S=I^<#YF.KK]_?U&0(N/#/L[G^;([MR^&?'ZLL4R7?,:HA.LNI:) *3O
MT/.3AO-YWA(!<4M#[=J<L4NU/02@S 0@M[\UE+<D*/X$//@66>>UIX\>FIL
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M@P'QQ[W03WY)T=L_+$5[7YMDT7;^*+]ZV/1N]5XEO%4GWALQ%$;/ ;1CR\9
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MO'7F_B17-?&S-0?4VT^3.X_:N@+-6@O:M/I1LN/37"KI<C@A &4N &G2YJB
M9PN=,^7\F9-9[TOF.+>?K+6F2:)3C=>VS1LD5Q<V]S>LH_V+K%M1D3+D<K($
M(/7TU'-PZ"9$1-S4MF5=I0F)N]]09ZJ #83"3./>X_=VW0( WQX(0-.$^$A<
M'KSMD7_=\-P8Q3\X1KV='V:JC77:>#85/GX(>'G]3?E].5SS20:'XJ/?38O;
MEQ=?>@>E>-\;^=6\!OE%3//^N"&$]O.I/L;,^L'N@QE%=3)KZROI'W02TL;C
M7KZ"[XUT E!%Z?PQ>[-HGU:[%_4A\<<V3,Z=/#[J%A(\@!P#9^/JY4["YJQW
M21X]:$@9"I!. -+<1I?.GTXNK)@J8F?&?$=6+_(/[]WM>\!,@ !498UYIE78
M1B.5 .2*?;GTA]GWB #DSLE7+YYEO53USG\HWT86 I *&$G[T6J:*'FLYPWU
MCCF\?U?. M"3A_<EE0?1S6M7@D<SIOU,QP/+0%ULRMN[PI]OV&HY[_4KEUFM
MPFI+,VC6^U8%FO6:BDO)CD^%L_8O7U(>'0)0Y@+0Q3.GPD)$P-/MS:OL]R5S
M? 'CXME3*<=+UZ'[_IR_R3I7[:S:-.4"D![![1M7G;Q=ME >RD?GBO]S[%!.
MS;^T<DFI5*U;+:>/'S7G0/WMLW,AA:]=OK^K& #X%D  FA;H3\2(\8!H[AR0
MPATOY$>M"E9DEX0WWC\QPL+RH?W@)/VVG]?)[U8\E)J773(RXH;CQT?-Q=#5
M.RSS-.RKR)T3*OC<]425;T$PU/P_9C]CMEBEN8]^OM0D?0/#XB9ES3C#<1Z1
M3@!:5;Y(.MO;Q_P=>K'J)7^.&#O'#NT?]?.> .1]UGZ^<\O&W+POK'$V1G,.
M I"ZXY\\=BCIY]0K2,.=[*\8@Y%B?=880A,D .EQGSAR,.DQYD(Z 4A%DEPX
M<^)H8HX,-;#*BN6#E[,G<VH"(F2V'D#G3I_T^BYHI)5X<V5L&)'IXKF<!"#]
MK%9$2FXT%\B+IX\GQ31TDU#[ E!XG:<RN%.U8,GN=&UE>:D1>5(='0)0Y@*0
M5NL*GB."85@]$UI=ROL%EJ/[DPLKVA[=OS?F&:S?<_+HP91S:[($($5S=YF"
M!+'9B=X_WLV2 E-8H,0I$Q\,S=NR?K7<NGXUH^3S  !3#0+0M,"MH* _AR/2
MV3LDF\XUR:^U3'QLZHUUVC@*'_I8I()'K?R_JA?RY&./C 1O&,73.!!;+S=W
M#,C\?6_DQZ)POI\9*AA.@^/+O-4&1$U;%/M/)0URI/JS] VZ(M#(=W?W+)T
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MLZES %TX<U)&QIA/2LL<']BS(S%<:9P$(&/HC#FWD\]$"D E$<-'!:#WN7H
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M#<BMF];+YT^M$H]>>">)#=.+\[>O7LB&RA6)E4P<PV3Q@KGRL*$VHU"ZZ2,
M^6BXQ)*%1:%*.7[2U)E27CQ/KE^Y*/VZ?QE<BZN7R9D3QXP8X&YC(I- (P!E
M)P U?7@G9?/FA 2@H">!SH7KE\X93QO7*$XW[.KI=?'<&5E45)C2&!U-  IO
M3X6.98%U-M-;,_I<O6"N7;X@7[_VC+)G-OW]?7+ETGEK#2^3!PUW$\6;>/@/
M_?-SVR=9IYYQ7D6OP'J?/U<N7SR?A0AD;[.[J].$D)E$N+$"6;EDH?G[[>M7
M&>7:&K ,__T[?PZ+-M[XSY052TJ=$#D_WULR@;^KLT..6$9_2:Q 4HEUW[H
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MV&L*#>C<*$[QG<$U;HH65)1)0]T=L]9T:[>O73$";++U-C8/( T!6R@=60A
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MZRX3OO6JY:M\^-PG[3W#,C X(I(@ZKC/(]X]D22A[C&.;T)+@-Q!  (
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M"@(0 ,!4DJ.F$X\C!@$     0.8@  $ 3#&92#G(/0      ,!80@
M    \AP$(         " / <!"          @ST$  @        #(<Q"
M      #R' 0@         ( \!P$(         "#/00 "         ,AS$(
M         /(<!"          @#P' 0@         (,]!  (         R',0
M@           \AP$(         " / <!"          @ST$  @        #(
M<Q"           #R' 0@         ( \!P$(         "#/00 "
M ,AS$(           /(<!"          @#P' 0@         (,]!  (
M    R',0@           \AP$(         " / <!"          @ST$  @
M      #(<Q"           #R' 0@         ( \!P$(         "#/00 "
M         ,AS$(           /(<!"          @#P' 0@         (,]!
M  (         R',0@           \AP$(         " / <!"          @
MST$  @        #(<Q"           #R' 0@         ( \!P$(
M "#/00 "         ,AS$(           /(<!"          @#P' 0@
M    (,]!  (         R',0@           \AP$(         " / <!"
M       @ST$  @        #(<Q"           #R' 0@         ( \!P$(
M         "#/00 "         ,AS$(           /(<!"          @#P'
M 0@         (,]!  (         R',0@           \AP$(         "
M/ <!"          @ST$  @        #(<Q"           #R' 0@
M ( \!P$(         "#/00 "         ,AS$(           /(<!"
M    @#P' 0@         (,]!  (         R',0@           \AP$(
M      " / <!"          @ST$  @        #(<Q"           #R' 0@
M         ( \!P$(         "#/00 "         ,AS$(           /(<
M!"          @#P' 0@         (,_Y_X]*<)( ICM      $E%3D2N0F""

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>7
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139758013219968">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Cover<br></strong></div></th>
<th class="th"><div>May 02, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">8-K<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">May  02,  2023<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">Arrowhead Pharmaceuticals, Inc.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-38042<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">46-0408024<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">177 E. Colorado Blvd<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine2', window );">Entity Address, Address Line Two</a></td>
<td class="text">Suite 700<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Pasadena<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">CA<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">91105<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">626<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">304-3400<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_WrittenCommunications', window );">Written Communications</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SolicitingMaterial', window );">Soliciting Material</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementTenderOffer', window );">Pre-commencement Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementIssuerTenderOffer', window );">Pre-commencement Issuer Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock, par value $0.001 per share<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">ARWR<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0000879407<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 2 such as Street or Suite number</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementIssuerTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 13e<br> -Subsection 4c<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementIssuerTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14d<br> -Subsection 2b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SolicitingMaterial">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Section 14a<br> -Number 240<br> -Subsection 12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SolicitingMaterial</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_WrittenCommunications">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 425<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_WrittenCommunications</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>8
<FILENAME>arwr-20230502_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xml:lang="en-US"
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2022"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="arwr-20230502.xsd" xlink:type="simple"/>
    <context id="i5f763463f13c4c3d89339b87605a4525_D20230502-20230502">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
        </entity>
        <period>
            <startDate>2023-05-02</startDate>
            <endDate>2023-05-02</endDate>
        </period>
    </context>
    <dei:EntityCentralIndexKey
      contextRef="i5f763463f13c4c3d89339b87605a4525_D20230502-20230502"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1ZTRjZmUzYmYyZTQ4NGY5MTFkYmU3NjYwOTlkOTAwL3NlYzpiNWU0Y2ZlM2JmMmU0ODRmOTExZGJlNzY2MDk5ZDkwMF80L2ZyYWc6ZjAwYWE3MTEwODdhNDc1Nzg5NjkzMzljMjkyNDNjNGEvdGFibGU6ZTk0NTYwZDhiYTM1NGZiMTg5ZWM5ZjRiMWNiNzY1NjYvdGFibGVyYW5nZTplOTQ1NjBkOGJhMzU0ZmIxODllYzlmNGIxY2I3NjU2Nl8yLTEtMS0xLTU5MzYw_a782bf31-b7dc-4fda-b3c0-91842cd5491f">0000879407</dei:EntityCentralIndexKey>
    <dei:AmendmentFlag
      contextRef="i5f763463f13c4c3d89339b87605a4525_D20230502-20230502"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1ZTRjZmUzYmYyZTQ4NGY5MTFkYmU3NjYwOTlkOTAwL3NlYzpiNWU0Y2ZlM2JmMmU0ODRmOTExZGJlNzY2MDk5ZDkwMF80L2ZyYWc6ZjAwYWE3MTEwODdhNDc1Nzg5NjkzMzljMjkyNDNjNGEvdGFibGU6ZTk0NTYwZDhiYTM1NGZiMTg5ZWM5ZjRiMWNiNzY1NjYvdGFibGVyYW5nZTplOTQ1NjBkOGJhMzU0ZmIxODllYzlmNGIxY2I3NjU2Nl8zLTEtMS0xLTU5MzYw_bfb933ef-27a4-4036-b680-89df7c81dc87">false</dei:AmendmentFlag>
    <dei:DocumentType
      contextRef="i5f763463f13c4c3d89339b87605a4525_D20230502-20230502"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1ZTRjZmUzYmYyZTQ4NGY5MTFkYmU3NjYwOTlkOTAwL3NlYzpiNWU0Y2ZlM2JmMmU0ODRmOTExZGJlNzY2MDk5ZDkwMF8xL2ZyYWc6NzJmNjBkNjM5YmI4NGIwYWFhOThjM2NlNGNjYjlmMWEvdGV4dHJlZ2lvbjo3MmY2MGQ2MzliYjg0YjBhYWE5OGMzY2U0Y2NiOWYxYV8xMjIw_12a6e8c1-5827-416b-9917-582b2733b13c">8-K</dei:DocumentType>
    <dei:DocumentPeriodEndDate
      contextRef="i5f763463f13c4c3d89339b87605a4525_D20230502-20230502"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1ZTRjZmUzYmYyZTQ4NGY5MTFkYmU3NjYwOTlkOTAwL3NlYzpiNWU0Y2ZlM2JmMmU0ODRmOTExZGJlNzY2MDk5ZDkwMF8xL2ZyYWc6NzJmNjBkNjM5YmI4NGIwYWFhOThjM2NlNGNjYjlmMWEvdGV4dHJlZ2lvbjo3MmY2MGQ2MzliYjg0YjBhYWE5OGMzY2U0Y2NiOWYxYV8xODM_e06d0e4d-eb45-4a52-9c8f-8fa06f3b63c4">2023-05-02</dei:DocumentPeriodEndDate>
    <dei:EntityRegistrantName
      contextRef="i5f763463f13c4c3d89339b87605a4525_D20230502-20230502"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1ZTRjZmUzYmYyZTQ4NGY5MTFkYmU3NjYwOTlkOTAwL3NlYzpiNWU0Y2ZlM2JmMmU0ODRmOTExZGJlNzY2MDk5ZDkwMF8xL2ZyYWc6NzJmNjBkNjM5YmI4NGIwYWFhOThjM2NlNGNjYjlmMWEvdGV4dHJlZ2lvbjo3MmY2MGQ2MzliYjg0YjBhYWE5OGMzY2U0Y2NiOWYxYV8xMjIx_b81e1b74-0563-41fa-9c18-1d1d7febca6e">Arrowhead Pharmaceuticals, Inc.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode
      contextRef="i5f763463f13c4c3d89339b87605a4525_D20230502-20230502"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1ZTRjZmUzYmYyZTQ4NGY5MTFkYmU3NjYwOTlkOTAwL3NlYzpiNWU0Y2ZlM2JmMmU0ODRmOTExZGJlNzY2MDk5ZDkwMF8xL2ZyYWc6NzJmNjBkNjM5YmI4NGIwYWFhOThjM2NlNGNjYjlmMWEvdGFibGU6Nzk3MTE1MTk1NDUwNDY3NWE4OThiZGQyMDQxOWRjMzgvdGFibGVyYW5nZTo3OTcxMTUxOTU0NTA0Njc1YTg5OGJkZDIwNDE5ZGMzOF8wLTAtMS0xLTU5MzYw_15258b8d-94f1-4913-9201-ffe2e06e274b">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityFileNumber
      contextRef="i5f763463f13c4c3d89339b87605a4525_D20230502-20230502"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1ZTRjZmUzYmYyZTQ4NGY5MTFkYmU3NjYwOTlkOTAwL3NlYzpiNWU0Y2ZlM2JmMmU0ODRmOTExZGJlNzY2MDk5ZDkwMF8xL2ZyYWc6NzJmNjBkNjM5YmI4NGIwYWFhOThjM2NlNGNjYjlmMWEvdGFibGU6Nzk3MTE1MTk1NDUwNDY3NWE4OThiZGQyMDQxOWRjMzgvdGFibGVyYW5nZTo3OTcxMTUxOTU0NTA0Njc1YTg5OGJkZDIwNDE5ZGMzOF8wLTItMS0xLTU5MzYw_18062f83-e7c6-449b-acca-a71a8c14d186">001-38042</dei:EntityFileNumber>
    <dei:EntityTaxIdentificationNumber
      contextRef="i5f763463f13c4c3d89339b87605a4525_D20230502-20230502"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1ZTRjZmUzYmYyZTQ4NGY5MTFkYmU3NjYwOTlkOTAwL3NlYzpiNWU0Y2ZlM2JmMmU0ODRmOTExZGJlNzY2MDk5ZDkwMF8xL2ZyYWc6NzJmNjBkNjM5YmI4NGIwYWFhOThjM2NlNGNjYjlmMWEvdGFibGU6Nzk3MTE1MTk1NDUwNDY3NWE4OThiZGQyMDQxOWRjMzgvdGFibGVyYW5nZTo3OTcxMTUxOTU0NTA0Njc1YTg5OGJkZDIwNDE5ZGMzOF8wLTQtMS0xLTU5MzYw_3054eb2a-89a7-449e-b5b5-26cce5bee138">46-0408024</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1
      contextRef="i5f763463f13c4c3d89339b87605a4525_D20230502-20230502"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1ZTRjZmUzYmYyZTQ4NGY5MTFkYmU3NjYwOTlkOTAwL3NlYzpiNWU0Y2ZlM2JmMmU0ODRmOTExZGJlNzY2MDk5ZDkwMF8xL2ZyYWc6NzJmNjBkNjM5YmI4NGIwYWFhOThjM2NlNGNjYjlmMWEvdGV4dHJlZ2lvbjo3MmY2MGQ2MzliYjg0YjBhYWE5OGMzY2U0Y2NiOWYxYV8xMjMy_4c73530f-c232-4df5-a138-267a5841f9ce">177 E. Colorado Blvd</dei:EntityAddressAddressLine1>
    <dei:EntityAddressAddressLine2
      contextRef="i5f763463f13c4c3d89339b87605a4525_D20230502-20230502"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1ZTRjZmUzYmYyZTQ4NGY5MTFkYmU3NjYwOTlkOTAwL3NlYzpiNWU0Y2ZlM2JmMmU0ODRmOTExZGJlNzY2MDk5ZDkwMF8xL2ZyYWc6NzJmNjBkNjM5YmI4NGIwYWFhOThjM2NlNGNjYjlmMWEvdGV4dHJlZ2lvbjo3MmY2MGQ2MzliYjg0YjBhYWE5OGMzY2U0Y2NiOWYxYV8xMjI2_c7a20f04-90e9-4306-b1f9-b0a42d620653">Suite 700</dei:EntityAddressAddressLine2>
    <dei:EntityAddressCityOrTown
      contextRef="i5f763463f13c4c3d89339b87605a4525_D20230502-20230502"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1ZTRjZmUzYmYyZTQ4NGY5MTFkYmU3NjYwOTlkOTAwL3NlYzpiNWU0Y2ZlM2JmMmU0ODRmOTExZGJlNzY2MDk5ZDkwMF8xL2ZyYWc6NzJmNjBkNjM5YmI4NGIwYWFhOThjM2NlNGNjYjlmMWEvdGV4dHJlZ2lvbjo3MmY2MGQ2MzliYjg0YjBhYWE5OGMzY2U0Y2NiOWYxYV8xMjI3_c0f045cf-86d3-4a3c-8234-4ca84ece3ada">Pasadena</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince
      contextRef="i5f763463f13c4c3d89339b87605a4525_D20230502-20230502"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1ZTRjZmUzYmYyZTQ4NGY5MTFkYmU3NjYwOTlkOTAwL3NlYzpiNWU0Y2ZlM2JmMmU0ODRmOTExZGJlNzY2MDk5ZDkwMF8xL2ZyYWc6NzJmNjBkNjM5YmI4NGIwYWFhOThjM2NlNGNjYjlmMWEvdGV4dHJlZ2lvbjo3MmY2MGQ2MzliYjg0YjBhYWE5OGMzY2U0Y2NiOWYxYV8xMjE5_dffa0ec4-a12b-4f60-ab48-80484e921ebf">CA</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode
      contextRef="i5f763463f13c4c3d89339b87605a4525_D20230502-20230502"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1ZTRjZmUzYmYyZTQ4NGY5MTFkYmU3NjYwOTlkOTAwL3NlYzpiNWU0Y2ZlM2JmMmU0ODRmOTExZGJlNzY2MDk5ZDkwMF8xL2ZyYWc6NzJmNjBkNjM5YmI4NGIwYWFhOThjM2NlNGNjYjlmMWEvdGV4dHJlZ2lvbjo3MmY2MGQ2MzliYjg0YjBhYWE5OGMzY2U0Y2NiOWYxYV8zODE_f6c4eed2-5e8a-4871-8167-8b6a0dbbbe8e">91105</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode
      contextRef="i5f763463f13c4c3d89339b87605a4525_D20230502-20230502"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1ZTRjZmUzYmYyZTQ4NGY5MTFkYmU3NjYwOTlkOTAwL3NlYzpiNWU0Y2ZlM2JmMmU0ODRmOTExZGJlNzY2MDk5ZDkwMF8xL2ZyYWc6NzJmNjBkNjM5YmI4NGIwYWFhOThjM2NlNGNjYjlmMWEvdGV4dHJlZ2lvbjo3MmY2MGQ2MzliYjg0YjBhYWE5OGMzY2U0Y2NiOWYxYV80NDY_291b4e61-e194-42fe-ad28-5b92de09b776">626</dei:CityAreaCode>
    <dei:LocalPhoneNumber
      contextRef="i5f763463f13c4c3d89339b87605a4525_D20230502-20230502"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1ZTRjZmUzYmYyZTQ4NGY5MTFkYmU3NjYwOTlkOTAwL3NlYzpiNWU0Y2ZlM2JmMmU0ODRmOTExZGJlNzY2MDk5ZDkwMF8xL2ZyYWc6NzJmNjBkNjM5YmI4NGIwYWFhOThjM2NlNGNjYjlmMWEvdGV4dHJlZ2lvbjo3MmY2MGQ2MzliYjg0YjBhYWE5OGMzY2U0Y2NiOWYxYV8xMjI5_fc597201-913c-4dee-9213-cf301935eb6a">304-3400</dei:LocalPhoneNumber>
    <dei:WrittenCommunications
      contextRef="i5f763463f13c4c3d89339b87605a4525_D20230502-20230502"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1ZTRjZmUzYmYyZTQ4NGY5MTFkYmU3NjYwOTlkOTAwL3NlYzpiNWU0Y2ZlM2JmMmU0ODRmOTExZGJlNzY2MDk5ZDkwMF8xL2ZyYWc6NzJmNjBkNjM5YmI4NGIwYWFhOThjM2NlNGNjYjlmMWEvdGFibGU6NjZiNTgzZjI0M2JmNDgxMGI3MTg2NzQ3N2ZjMDdlMTEvdGFibGVyYW5nZTo2NmI1ODNmMjQzYmY0ODEwYjcxODY3NDc3ZmMwN2UxMV8wLTAtMS0xLTU5MzYw_b8483cd4-d3d9-4dd8-9203-d8eb6c32dfb9">false</dei:WrittenCommunications>
    <dei:SolicitingMaterial
      contextRef="i5f763463f13c4c3d89339b87605a4525_D20230502-20230502"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1ZTRjZmUzYmYyZTQ4NGY5MTFkYmU3NjYwOTlkOTAwL3NlYzpiNWU0Y2ZlM2JmMmU0ODRmOTExZGJlNzY2MDk5ZDkwMF8xL2ZyYWc6NzJmNjBkNjM5YmI4NGIwYWFhOThjM2NlNGNjYjlmMWEvdGFibGU6NjZiNTgzZjI0M2JmNDgxMGI3MTg2NzQ3N2ZjMDdlMTEvdGFibGVyYW5nZTo2NmI1ODNmMjQzYmY0ODEwYjcxODY3NDc3ZmMwN2UxMV8xLTAtMS0xLTU5MzYw_c616ebf6-d6fa-4acf-a4c1-2d7ea5ed6eb3">false</dei:SolicitingMaterial>
    <dei:PreCommencementTenderOffer
      contextRef="i5f763463f13c4c3d89339b87605a4525_D20230502-20230502"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1ZTRjZmUzYmYyZTQ4NGY5MTFkYmU3NjYwOTlkOTAwL3NlYzpiNWU0Y2ZlM2JmMmU0ODRmOTExZGJlNzY2MDk5ZDkwMF8xL2ZyYWc6NzJmNjBkNjM5YmI4NGIwYWFhOThjM2NlNGNjYjlmMWEvdGFibGU6NjZiNTgzZjI0M2JmNDgxMGI3MTg2NzQ3N2ZjMDdlMTEvdGFibGVyYW5nZTo2NmI1ODNmMjQzYmY0ODEwYjcxODY3NDc3ZmMwN2UxMV8yLTAtMS0xLTU5MzYw_3e86b1d6-d0aa-4fc9-949b-7e640bf52201">false</dei:PreCommencementTenderOffer>
    <dei:PreCommencementIssuerTenderOffer
      contextRef="i5f763463f13c4c3d89339b87605a4525_D20230502-20230502"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1ZTRjZmUzYmYyZTQ4NGY5MTFkYmU3NjYwOTlkOTAwL3NlYzpiNWU0Y2ZlM2JmMmU0ODRmOTExZGJlNzY2MDk5ZDkwMF8xL2ZyYWc6NzJmNjBkNjM5YmI4NGIwYWFhOThjM2NlNGNjYjlmMWEvdGFibGU6NjZiNTgzZjI0M2JmNDgxMGI3MTg2NzQ3N2ZjMDdlMTEvdGFibGVyYW5nZTo2NmI1ODNmMjQzYmY0ODEwYjcxODY3NDc3ZmMwN2UxMV8zLTAtMS0xLTU5MzYw_12db5cb2-b3a0-41ab-9cb2-7bc5d690e0b8">false</dei:PreCommencementIssuerTenderOffer>
    <dei:Security12bTitle
      contextRef="i5f763463f13c4c3d89339b87605a4525_D20230502-20230502"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1ZTRjZmUzYmYyZTQ4NGY5MTFkYmU3NjYwOTlkOTAwL3NlYzpiNWU0Y2ZlM2JmMmU0ODRmOTExZGJlNzY2MDk5ZDkwMF8xL2ZyYWc6NzJmNjBkNjM5YmI4NGIwYWFhOThjM2NlNGNjYjlmMWEvdGFibGU6MTAxNzJiOTQ0OTg1NDA3NzhmZTNlODBmYzdiYmNmYWEvdGFibGVyYW5nZToxMDE3MmI5NDQ5ODU0MDc3OGZlM2U4MGZjN2JiY2ZhYV8yLTAtMS0xLTU5MzYw_ef781d5c-8cf1-41f9-94f7-9012677bd841">Common Stock, par value $0.001 per share</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="i5f763463f13c4c3d89339b87605a4525_D20230502-20230502"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1ZTRjZmUzYmYyZTQ4NGY5MTFkYmU3NjYwOTlkOTAwL3NlYzpiNWU0Y2ZlM2JmMmU0ODRmOTExZGJlNzY2MDk5ZDkwMF8xL2ZyYWc6NzJmNjBkNjM5YmI4NGIwYWFhOThjM2NlNGNjYjlmMWEvdGFibGU6MTAxNzJiOTQ0OTg1NDA3NzhmZTNlODBmYzdiYmNmYWEvdGFibGVyYW5nZToxMDE3MmI5NDQ5ODU0MDc3OGZlM2U4MGZjN2JiY2ZhYV8yLTItMS0xLTU5MzYw_2e430b4f-6dcc-4511-8b7e-a92fd276b56d">ARWR</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="i5f763463f13c4c3d89339b87605a4525_D20230502-20230502"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1ZTRjZmUzYmYyZTQ4NGY5MTFkYmU3NjYwOTlkOTAwL3NlYzpiNWU0Y2ZlM2JmMmU0ODRmOTExZGJlNzY2MDk5ZDkwMF8xL2ZyYWc6NzJmNjBkNjM5YmI4NGIwYWFhOThjM2NlNGNjYjlmMWEvdGFibGU6MTAxNzJiOTQ0OTg1NDA3NzhmZTNlODBmYzdiYmNmYWEvdGFibGVyYW5nZToxMDE3MmI5NDQ5ODU0MDc3OGZlM2U4MGZjN2JiY2ZhYV8yLTQtMS0xLTU5MzYw_0e78669f-314b-4f42-a21a-9de2c479d41d">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityEmergingGrowthCompany
      contextRef="i5f763463f13c4c3d89339b87605a4525_D20230502-20230502"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1ZTRjZmUzYmYyZTQ4NGY5MTFkYmU3NjYwOTlkOTAwL3NlYzpiNWU0Y2ZlM2JmMmU0ODRmOTExZGJlNzY2MDk5ZDkwMF8xL2ZyYWc6NzJmNjBkNjM5YmI4NGIwYWFhOThjM2NlNGNjYjlmMWEvdGV4dHJlZ2lvbjo3MmY2MGQ2MzliYjg0YjBhYWE5OGMzY2U0Y2NiOWYxYV8xMjI1_677fa574-7029-428a-a150-d06a5307c679">false</dei:EntityEmergingGrowthCompany>
    <dei:DocumentPeriodEndDate
      contextRef="i5f763463f13c4c3d89339b87605a4525_D20230502-20230502"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1ZTRjZmUzYmYyZTQ4NGY5MTFkYmU3NjYwOTlkOTAwL3NlYzpiNWU0Y2ZlM2JmMmU0ODRmOTExZGJlNzY2MDk5ZDkwMF83L2ZyYWc6ZWI2MjQyOTA3MTBjNGJkOThiODQyMzRmNDQ3N2RkZGQvdGV4dHJlZ2lvbjplYjYyNDI5MDcxMGM0YmQ5OGI4NDIzNGY0NDc3ZGRkZF82NQ_e06d0e4d-eb45-4a52-9c8f-8fa06f3b63c4">2023-05-02</dei:DocumentPeriodEndDate>
    <dei:DocumentPeriodEndDate
      contextRef="i5f763463f13c4c3d89339b87605a4525_D20230502-20230502"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1ZTRjZmUzYmYyZTQ4NGY5MTFkYmU3NjYwOTlkOTAwL3NlYzpiNWU0Y2ZlM2JmMmU0ODRmOTExZGJlNzY2MDk5ZDkwMF8xMy9mcmFnOjNjYTYxODUzMzY0YzQ0ODE5OTEyZThlMjg2NmMxZGUzL3RleHRyZWdpb246M2NhNjE4NTMzNjRjNDQ4MTk5MTJlOGUyODY2YzFkZTNfMjA5_e06d0e4d-eb45-4a52-9c8f-8fa06f3b63c4">2023-05-02</dei:DocumentPeriodEndDate>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>9
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M=]W3CHG&K=!X#;[Q3X?#KHG&J]!TZVDF)_VN:Z3I%FA"1N/K>A(5M>5 TR
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M!Z.:60F]A%9JGZJ'-#ZH'C(*!?&Y'C[E>G@*-Y;&O%"N@GL!_]':-\*K^(+
M.7\N?<^E[[GT/:'2MS<C?6?!TXM;WD9N6\3[KC':US0N*&-7<LW(QU2ODRG8
M.9_ [/UH/I[Q[?K9)(2OFEDM(Q:02X&S022X_(O*\"K$">AD6R4)RU3393>*
M$IY"&V[I4_5*E=?EK[DHN#Q;Y.FOH70^+,_Y/%_GM,T+,T.W<DOJMI2^M28X
M2O2QS'!.'LL,.V<\DAVV=Z =-?OV77;D(Z4P4Y=#N!I"O@-MNIW<.CB>F)&Y
M"M-2D&_#^>G%>!KB.=D$N7V85VWGV-'1^^?!4;"C[SR6'<>(\J(A[J&&F,_#
M0X=Y>U^89Y7&4#04;6RL)"Q&MV"XU_$L%.!D8"V@!X.O40+R4E5@,5O& RN0
MHGQ,C$7H<.>77%_CT9+CVZ9EM6ZO*7<9;2)2.<)IF!-GJ\K>9;'!51W/55OR
ML+YJ/;053L_^6:W(GPP13A8+$DACE!>F2J+S&5.^YRM)Q%4XOT4SMA*7&+SC
MYL=Q3E.X$G:V#P(RN;LYJ7IE,6>F\M\M# DL6XA9$N)-7>W5YYN<KGHB=OJ7
M=\%@\OUPR4</Y3OG7_1=0ZY^]MWC^FZ3.TA,G'G%$0%T10(CE1P&%A<RY%#N
MDI &$P'-E,E$\ *"9*8<@)CZ"[WR#+DI%<ZM/CE_12R#ADY>TB42%(JP# 4A
M%W+C[^^3:G>,U_HL@6V$5#)DU1?*0XG!/3-R0]A4)?.NVB8+A=OB5,V[&KXF
M8$O#>FZ=+2?_VU[4/;07/4;SHYG@'K.'<YMZN,)%K/]8UA[Y,M\Y<-LZW@->
MYA,L0Z1^P7V*BH 1JV*^NJ]/^26<.[1[\8$@F_S6VZ3VW> ,?-2K6J5D*Q$_
M2P=\'Y(&8XQ;]#1?CQ1BK::QK<;:,0QY@%CS#*%F.-^'19H:,]6+K#F-"F]!
MU4#E/]O4#6CV#30<D05>,9FV-J/D3@H\W/[O#;#"Q([A[8N_ 5!+ P04
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M"H[<8R6,<6*T_C6"R0_L?@!02P,$%     @ -8&B5JK$(A8S 0  (@(   \
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M4$L! A0#%     @ -8&B5JQPN2[O    *P(  !$              ( !KP
M &1O8U!R;W!S+V-O<F4N>&UL4$L! A0#%     @ -8&B5IE<G",0!@  G"<
M !,              ( !S0$  'AL+W1H96UE+W1H96UE,2YX;6Q02P$"% ,4
M    "  U@:)6^[9I=F$$   H$0  &               @($."   >&PO=V]R
M:W-H965T<R]S:&5E=#$N>&UL4$L! A0#%     @ -8&B5I^@&_"Q @  X@P
M  T              ( !I0P  'AL+W-T>6QE<RYX;6Q02P$"% ,4    "  U
M@:)6EXJ[',     3 @  "P              @ &!#P  7W)E;',O+G)E;'-0
M2P$"% ,4    "  U@:)6JL0B%C,!   B @  #P              @ %J$
M>&PO=V]R:V)O;VLN>&UL4$L! A0#%     @ -8&B5B0>FZ*M    ^ $  !H
M             ( !RA$  'AL+U]R96QS+W=O<FMB;V]K+GAM;"YR96QS4$L!
M A0#%     @ -8&B5F60>9(9 0  SP,  !,              ( !KQ(  %M#
G;VYT96YT7U1Y<&5S72YX;6Q02P4&      D "0 ^ @  ^1,

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>10
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>11
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>12
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.23.1</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>1</ContextCount>
  <ElementCount>23</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>0</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>0</UnitCount>
  <MyReports>
    <Report instance="arwr-20230502.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>0000001 - Document - Cover</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arrowheadresearch.com/role/Cover</Role>
      <ShortName>Cover</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="8-K" original="arwr-20230502.htm">arwr-20230502.htm</File>
    <File>arwr-20230502.xsd</File>
    <File>arwr-20230502_lab.xml</File>
    <File>arwr-20230502_pre.xml</File>
    <File>arwr-fq22023financialresul.htm</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy items="25">http://xbrl.sec.gov/dei/2022</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>false</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>14
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "arwr-20230502.htm": {
   "axisCustom": 0,
   "axisStandard": 0,
   "baseTaxonomies": {
    "http://xbrl.sec.gov/dei/2022": 25
   },
   "contextCount": 1,
   "dts": {
    "inline": {
     "local": [
      "arwr-20230502.htm"
     ]
    },
    "labelLink": {
     "local": [
      "arwr-20230502_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "arwr-20230502_pre.xml"
     ]
    },
    "schema": {
     "local": [
      "arwr-20230502.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://xbrl.sec.gov/dei/2022/dei-2022.xsd"
     ]
    }
   },
   "elementCount": 24,
   "entityCount": 1,
   "hidden": {
    "http://xbrl.sec.gov/dei/2022": 2,
    "total": 2
   },
   "keyCustom": 0,
   "keyStandard": 23,
   "memberCustom": 0,
   "memberStandard": 0,
   "nsprefix": "arwr",
   "nsuri": "http://www.arrowheadresearch.com/20230502",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "arwr-20230502.htm",
      "contextRef": "i5f763463f13c4c3d89339b87605a4525_D20230502-20230502",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "0000001 - Document - Cover",
     "menuCat": "Cover",
     "order": "1",
     "role": "http://www.arrowheadresearch.com/role/Cover",
     "shortName": "Cover",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "arwr-20230502.htm",
      "contextRef": "i5f763463f13c4c3d89339b87605a4525_D20230502-20230502",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    }
   },
   "segmentCount": 0,
   "tag": {
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag",
        "terseLabel": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_CityAreaCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Area code of city",
        "label": "City Area Code",
        "terseLabel": "City Area Code"
       }
      }
     },
     "localname": "CityAreaCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CoverAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cover page.",
        "label": "Cover [Abstract]"
       }
      }
     },
     "localname": "CoverAbstract",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "xbrltype": "stringItemType"
    },
    "dei_DocumentPeriodEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.",
        "label": "Document Period End Date",
        "terseLabel": "Document Period End Date"
       }
      }
     },
     "localname": "DocumentPeriodEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/Cover"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document Type",
        "terseLabel": "Document Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/Cover"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_EntityAddressAddressLine1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name",
        "label": "Entity Address, Address Line One",
        "terseLabel": "Entity Address, Address Line One"
       }
      }
     },
     "localname": "EntityAddressAddressLine1",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressAddressLine2": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 2 such as Street or Suite number",
        "label": "Entity Address, Address Line Two",
        "terseLabel": "Entity Address, Address Line Two"
       }
      }
     },
     "localname": "EntityAddressAddressLine2",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCityOrTown": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the City or Town",
        "label": "Entity Address, City or Town",
        "terseLabel": "Entity Address, City or Town"
       }
      }
     },
     "localname": "EntityAddressCityOrTown",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressPostalZipCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Code for the postal or zip code",
        "label": "Entity Address, Postal Zip Code",
        "terseLabel": "Entity Address, Postal Zip Code"
       }
      }
     },
     "localname": "EntityAddressPostalZipCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressStateOrProvince": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the state or province.",
        "label": "Entity Address, State or Province",
        "terseLabel": "Entity Address, State or Province"
       }
      }
     },
     "localname": "EntityAddressStateOrProvince",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/Cover"
     ],
     "xbrltype": "stateOrProvinceItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity Central Index Key",
        "terseLabel": "Entity Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/Cover"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Entity Emerging Growth Company",
        "terseLabel": "Entity Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFileNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
        "label": "Entity File Number",
        "terseLabel": "Entity File Number"
       }
      }
     },
     "localname": "EntityFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/Cover"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_EntityIncorporationStateCountryCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two-character EDGAR code representing the state or country of incorporation.",
        "label": "Entity Incorporation, State or Country Code",
        "terseLabel": "Entity Incorporation, State or Country Code"
       }
      }
     },
     "localname": "EntityIncorporationStateCountryCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/Cover"
     ],
     "xbrltype": "edgarStateCountryItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity Registrant Name",
        "terseLabel": "Entity Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityTaxIdentificationNumber": {
     "auth_ref": [
      "r1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.",
        "label": "Entity Tax Identification Number",
        "terseLabel": "Entity Tax Identification Number"
       }
      }
     },
     "localname": "EntityTaxIdentificationNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/Cover"
     ],
     "xbrltype": "employerIdItemType"
    },
    "dei_LocalPhoneNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Local phone number for entity.",
        "label": "Local Phone Number",
        "terseLabel": "Local Phone Number"
       }
      }
     },
     "localname": "LocalPhoneNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_PreCommencementIssuerTenderOffer": {
     "auth_ref": [
      "r3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.",
        "label": "Pre-commencement Issuer Tender Offer",
        "terseLabel": "Pre-commencement Issuer Tender Offer"
       }
      }
     },
     "localname": "PreCommencementIssuerTenderOffer",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_PreCommencementTenderOffer": {
     "auth_ref": [
      "r4"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.",
        "label": "Pre-commencement Tender Offer",
        "terseLabel": "Pre-commencement Tender Offer"
       }
      }
     },
     "localname": "PreCommencementTenderOffer",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_Security12bTitle": {
     "auth_ref": [
      "r0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Title of a 12(b) registered security.",
        "label": "Title of 12(b) Security",
        "terseLabel": "Title of 12(b) Security"
       }
      }
     },
     "localname": "Security12bTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/Cover"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_SecurityExchangeName": {
     "auth_ref": [
      "r2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the Exchange on which a security is registered.",
        "label": "Security Exchange Name",
        "terseLabel": "Security Exchange Name"
       }
      }
     },
     "localname": "SecurityExchangeName",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/Cover"
     ],
     "xbrltype": "edgarExchangeCodeItemType"
    },
    "dei_SolicitingMaterial": {
     "auth_ref": [
      "r5"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.",
        "label": "Soliciting Material",
        "terseLabel": "Soliciting Material"
       }
      }
     },
     "localname": "SolicitingMaterial",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_TradingSymbol": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Trading symbol of an instrument as listed on an exchange.",
        "label": "Trading Symbol",
        "terseLabel": "Trading Symbol"
       }
      }
     },
     "localname": "TradingSymbol",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/Cover"
     ],
     "xbrltype": "tradingSymbolItemType"
    },
    "dei_WrittenCommunications": {
     "auth_ref": [
      "r6"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.",
        "label": "Written Communications",
        "terseLabel": "Written Communications"
       }
      }
     },
     "localname": "WrittenCommunications",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    }
   },
   "unitCount": 0
  }
 },
 "std_ref": {
  "r0": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r1": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r2": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "d1-1",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r3": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13e",
   "Subsection": "4c",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r4": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "14d",
   "Subsection": "2b",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r5": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "14a",
   "Subsection": "12",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r6": {
   "Name": "Securities Act",
   "Number": "230",
   "Publisher": "SEC",
   "Section": "425",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  }
 },
 "version": "2.2"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>15
<FILENAME>0001628280-23-014859-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001628280-23-014859-xbrl.zip
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MJG7>C:,H2--7L*Q"U:,"!-]6]($5;;8/43T:A?&,)YN^IM<U''+B\EU+N^[
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MW&/75\I&?73*QPI+__V)N7TB^YDO!EU'8J\PV-8J0Q<W*]X[?M]_,856$,?
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M<B%R>GIZI@-C)N<U+%.3#N3%IO<Y/^S]L[[F&GCE^ESR5]?YC[&^5U. D+D
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MKI%U6*&N%)Q8F V];R5(FZM..JP9ZDU^-OCKJK-^[R"V_(<LWK%Y65!>-AE
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M"8P3?/D^7;2;IL)U+8I8>DR$  LKG TQP6B41[@2<^E2E#M<+_XTW L*\X-
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MXIWA@:.]NP_R0_[7B:.]_P%02P,$%     @ -8&B5HVI(_8R'@  9!D! !X
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M_H=']N@] UP+ 3=@A?S^YX._"#@(LNC'RW0F4$'!="B,:"E&/EN[$2IVPJ.
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M>ST141>P0?I^B"YD<8$C8#A.GP<R]G%#8> 0"1S#^UP+6A6A18]TDXB&=AU
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MKEM6X'B]W6K5@ 4$P\DNI-TTFYA3N,\&(+X[ G)1:('!8:TB)(23$9+Y0 8
MC8 O^0:.X,/MHRVR;S!<I/N>]*6>)(? +K""GHX)OYBPI^"\Q08J<F,6)TZ?
M\9@A;RF7P!:&%OUI'V:'!M+S9H_A%[(Z>O9H!R@CL)O9PSP XB.!X<R=Z:MP
M[A@2OL"=/1IZ/)@[%JD_%_3"48DW=[\ 0_87] !5)(-D[K@AHK-'47H.CW5V
M&-0WT\[$&11W('J4!:?B!\T;J<-I12\LW'#P&$U61]03KH-S#H8=0X_QO2$9
M@,?U@)02BT+Q&).06)T#_S1*O,LZ3@.,:])P+SYMI<21(WPS"=M,A9KY@4J
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MY59<O6'PWXZN!-SO*'<(O_K:]S[^#U!+ 0(4 Q0    ( #6!HE:-^F[QJ!4
M !.6   1              "  0    !A<G=R+3(P,C,P-3 R+FAT;5!+ 0(4
M Q0    ( #6!HE9TL_L@; (  (D'   1              "  =<5  !A<G=R
M+3(P,C,P-3 R+GAS9%!+ 0(4 Q0    ( #6!HE;?B9=KCPH  !%A   5
M          "  7(8  !A<G=R+3(P,C,P-3 R7VQA8BYX;6Q02P$"% ,4
M"  U@:)6]M0/FMH&   (,P  %0              @ $T(P  87)W<BTR,#(S
M,#4P,E]P<F4N>&UL4$L! A0#%     @ -8&B5HVI(_8R'@  9!D! !X
M         ( !02H  &%R=W(M9G$R,C R,V9I;F%N8VEA;')E<W5L+FAT;5!+
4!08     !0 % % !  "O2      !

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
